<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Adv</journal-id><journal-id journal-id-type="iso-abbrev">Sci Adv</journal-id><journal-id journal-id-type="publisher-id">sciadv</journal-id><journal-id journal-id-type="hwp">advances</journal-id><journal-title-group><journal-title>Science Advances</journal-title></journal-title-group><issn pub-type="epub">2375-2548</issn><publisher><publisher-name>American Association for the Advancement of Science</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40009690</article-id><article-id pub-id-type="pmc">PMC11864192</article-id><article-id pub-id-type="publisher-id">ads1482</article-id><article-id pub-id-type="doi">10.1126/sciadv.ads1482</article-id><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biomedicine and Life Sciences</subject></subj-group><subj-group subj-group-type="legacy-article-type"><subject>SciAdv r-articles</subject></subj-group><subj-group subj-group-type="field"><subject>Immunology</subject><subject>Virology</subject></subj-group><subj-group subj-group-type="overline"><subject>Coronavirus</subject></subj-group></article-categories><title-group><article-title>Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant</article-title><alt-title alt-title-type="short">Elevated SARS-CoV-2 IgG4 can have variable functional consequences</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-5683-8852</contrib-id><name><surname>Aurelia</surname><given-names>L. Carissa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6378-5114</contrib-id><name><surname>Purcell</surname><given-names>Ruth A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2097-8650</contrib-id><name><surname>Theisen</surname><given-names>Robert M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2719-6544</contrib-id><name><surname>Kelly</surname><given-names>Andrew</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7091-0048</contrib-id><name><surname>Esterbauer</surname><given-names>Robyn</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7390-8840</contrib-id><name><surname>Ramanathan</surname><given-names>Pradhipa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7285-4054</contrib-id><name><surname>Lee</surname><given-names>Wen Shi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4108-375X</contrib-id><name><surname>Wines</surname><given-names>Bruce D.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hogarth</surname><given-names>P. Mark</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9072-1017</contrib-id><name><surname>Juno</surname><given-names>Jennifer A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4197-2573</contrib-id><name><surname>Allen</surname><given-names>Lilith F.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4473-9232</contrib-id><name><surname>Bond</surname><given-names>Katherine A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7363-6665</contrib-id><name><surname>Williamson</surname><given-names>Deborah A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8660-5558</contrib-id><name><surname>Trevillyan</surname><given-names>Janine M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Trubiano</surname><given-names>Jason A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9294-7693</contrib-id><name><surname>Nguyen</surname><given-names>Thi HO</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6141-335X</contrib-id><name><surname>Kedzierska</surname><given-names>Katherine</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5593-9387</contrib-id><name><surname>Wheatley</surname><given-names>Adam K.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8539-4891</contrib-id><name><surname>Kent</surname><given-names>Stephen J.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4756-7461</contrib-id><name><surname>Arnold</surname><given-names>Kelly B.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0780-9422</contrib-id><name><surname>Selva</surname><given-names>Kevin John</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0020-9704</contrib-id><name><surname>Chung</surname><given-names>Amy W.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.</aff><aff id="aff2"><label><sup>2</sup></label>Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.</aff><aff id="aff3"><label><sup>3</sup></label>Immune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.</aff><aff id="aff4"><label><sup>4</sup></label>Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.</aff><aff id="aff5"><label><sup>5</sup></label>Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.</aff><aff id="aff6"><label><sup>6</sup></label>Victorian Infectious Disease Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.</aff><aff id="aff7"><label><sup>7</sup></label>Department of Microbiology, Royal Melbourne Hospital, Melbourne, VIC, Australia.</aff><aff id="aff8"><label><sup>8</sup></label>Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.</aff><aff id="aff9"><label><sup>9</sup></label>School of Medicine, University of St Andrews, Fife KY16 9TF, Scotland.</aff><aff id="aff10"><label><sup>10</sup></label>Department of Infectious Diseases and Immunology, Austin Health, Heidelberg, VIC, Australia.</aff><aff id="aff11"><label><sup>11</sup></label>Centre for Antibiotic Allergy and Research, National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.</aff><aff id="aff12"><label><sup>12</sup></label>Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University, Melbourne, VIC, Australia.</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Email: <email xlink:href="awchung@unimelb.edu.au">awchung@unimelb.edu.au</email></corresp></author-notes><pub-date pub-type="collection"><day>28</day><month>2</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="pub"><day>26</day><month>2</month><year>2025</year></pub-date><volume>11</volume><issue>9</issue><elocation-id>eads1482</elocation-id><history>
<date date-type="received"><day>31</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>23</day><month>1</month><year>2025</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2025 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-02-26">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution license</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="sciadv.ads1482.pdf"/><abstract><p>Repeated mRNA COVID-19 vaccination increases spike-specific immunoglobulin G4 (IgG4) titers. Here, we characterized the influence of increased IgG4 titers on a range of Fc-mediated responses. Elevated spike-specific IgG4 reduced binding to Fc&#x003b3;RIIIa and decreased antibody-dependent cellular cytotoxicity. However, in individuals with lower total spike-specific IgG, IgG4 acted in synergy with other IgG subclasses to improve Fc&#x003b3;RI and Fc&#x003b3;RIIa binding and consequently antibody-dependent cellular phagocytosis. Furthermore, this trend was more pronounced with more recent SARS-CoV-2 variants where vaccination induced comparably lower total spike-specific titers. These observations were further confirmed by in silico modeling where antibody subclass concentrations and Fc&#x003b3;R polymorphisms were modulated. Collectively, we illustrate that the impact of elevated IgG4 titers upon Fc functions is dependent on multiple interconnected antibody and antigen factors, which should be taken into consideration when dissecting the mechanisms driving an effective Fc-mediated response following vaccination.</p></abstract><abstract abstract-type="teaser"><p>Elevated SARS-CoV-2&#x02013;specific IgG4 titers decrease ADCC but can increase ADCP when spike-specific antibody titers are low.</p></abstract><funding-group><award-group id="award1729069"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NHMRC</institution></institution-wrap>
</funding-source><award-id>#2008093</award-id></award-group><award-group id="award1729068"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Medical Research Future Fund</institution></institution-wrap>
</funding-source><award-id>GNT #2016062</award-id></award-group><award-group id="award1860344"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Sylvia and Charles Viertel Senior Medical Research Fellowship</institution></institution-wrap>
</funding-source></award-group><award-group id="award1906405"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NHMRC Investigator Grants</institution></institution-wrap>
</funding-source></award-group><award-group id="award1906406"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NHMRC Investigator Grants</institution></institution-wrap>
</funding-source></award-group><award-group id="award1906407"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NHMRC Investigator Grants</institution></institution-wrap>
</funding-source></award-group><award-group id="award1906408"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NHMRC Investigator Grants</institution></institution-wrap>
</funding-source></award-group><award-group id="award1906409"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NHMRC Investigator Grants</institution></institution-wrap>
</funding-source></award-group><award-group id="award1906410"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>NHMRC Investigator Grants</institution></institution-wrap>
</funding-source></award-group><award-group id="award1906389"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Medical Research Future Fund (MRFF)</institution></institution-wrap>
</funding-source><award-id>GNT #2016062</award-id></award-group><award-group id="award1906392"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Medical Research Future Fund (MRFF)</institution></institution-wrap>
</funding-source><award-id>GNT #2016062</award-id></award-group><award-group id="award1906387"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Medical Research Future Fund (MRFF)</institution></institution-wrap>
</funding-source><award-id>GNT #2016062</award-id></award-group><award-group id="award1906388"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Medical Research Future Fund (MRFF)</institution></institution-wrap>
</funding-source><award-id>GNT #2016062</award-id></award-group><award-group id="award1906390"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Medical Research Future Fund (MRFF)</institution></institution-wrap>
</funding-source><award-id>GNT #2016062</award-id></award-group><award-group id="award1906391"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Medical Research Future Fund (MRFF)</institution></institution-wrap>
</funding-source><award-id>GNT #2016062</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="introduction" disp-level="1"><title>INTRODUCTION</title><p>Coronavirus disease 2019 (COVID-19) vaccination elicits high titers of spike-specific antibodies. These antibodies can provide protection through direct neutralization of the virus (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>) along with the coordination of innate immune responses via the crystallizable (Fc) region (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>&#x02013;<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). These Fc effector functions are induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#x02013;specific immunoglobulin G (IgG) antibodies, which form immune complexes with Fc gamma receptors (Fc&#x003b3;Rs) expressed on innate immune cells to activate downstream effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>). Multiple studies have highlighted the contribution of Fc-mediated responses in providing protection against SARS-CoV-2 (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>&#x02013;<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). A growing number of studies have highlighted the maintenance of Fc effector functions against emerging SARS-CoV-2 variants that evade neutralizing antibodies (<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>&#x02013;<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>).</p><p>The induction of Fc-mediated responses is dependent on the ability of IgG to engage with both its target antigen and the Fc&#x003b3;R, both of which are modulated by the biophysical features of the IgG, the Fc&#x003b3;R, and the attributes of the target pathogen. This includes the four IgG subclasses (IgG1 to IgG4), which vary in their affinities for Fc&#x003b3;Rs and ability to activate Fc&#x003b3;R-mediated responses (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>, <xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>). Of the four, IgG1 and IgG3 display high capacity to engage with Fc&#x003b3;Rs, and high titers of these subclasses have been demonstrated to orchestrate polyfunctional antibody responses (<xref rid="R12" ref-type="bibr"><italic toggle="yes">12</italic></xref>, <xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>). In contrast, IgG2 and IgG4 are poor inducers of Fc-mediated responses due to their reduced ability to bind activating Fc&#x003b3;Rs, with several studies suggesting that the presence of IgG2 and IgG4 may impede the Fc effector functions mediated by IgG1 or IgG3 (<xref rid="R12" ref-type="bibr"><italic toggle="yes">12</italic></xref>, <xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>, <xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>).</p><p>In parallel to the four IgG subclasses, multiple classes of Fc&#x003b3;Rs exist that vary in affinity for IgG subclasses. Fc&#x003b3;RI is the sole high-affinity Fc&#x003b3;R in humans and can bind all IgG subclasses, except IgG2 (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>). In contrast, Fc&#x003b3;RIIa and Fc&#x003b3;RIIIa are low-affinity receptors that are activated through cross-linking by antigen-bound IgG (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>). Two main Fc&#x003b3;RIIa polymorphisms have been identified: Fc&#x003b3;RIIa-H131 and Fc&#x003b3;RIIa-R131. Similarly, there are two main Fc&#x003b3;RIIIa polymorphisms: Fc&#x003b3;RIIIa-V158 and Fc&#x003b3;RIIIa-F158. Fc&#x003b3;RIIa-H131 and Fc&#x003b3;RIIIa-V158 display higher affinity for IgG1 and IgG3 compared to Fc&#x003b3;RIIa-R131 and Fc&#x003b3;RIIIa-F158, respectively (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>). Moreover, IgG4 can weakly bind Fc&#x003b3;RIIIa-V158 but not Fc&#x003b3;RIIIa-F158 and has higher affinity for Fc&#x003b3;RIIa-R131 compared to Fc&#x003b3;RIIa-H131 (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>). Consequently, Fc functions are dictated by IgG subclass as well as Fc&#x003b3;R class and polymorphism.</p><p>Intriguingly, multiple studies have reported a rise in spike-specific IgG4 with repeated mRNA vaccination (<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>&#x02013;<xref rid="R19" ref-type="bibr"><italic toggle="yes">19</italic></xref>). We have previously demonstrated that elevated IgG4 is negatively correlated with Fc&#x003b3;R engagement (<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>). Moreover, Irrgang <italic toggle="yes">et al.</italic> (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>) reported a decline in ADCP accompanying the increase in IgG4, suggesting that elevated IgG4 inhibits Fc effector functions. However, mechanistic studies on the functional consequence of increased IgG4 are now limited especially in regard to ADCC responses and Fc&#x003b3;R engagement. Moreover, little is known about how elevated IgG4 influences Fc-mediated responses against SARS-CoV-2 variants.</p><p>Here, we demonstrate that IgG4 poorly binds Fc&#x003b3;RIIIa, and thus, elevated IgG4 titers impede ADCC. In contrast, IgG4 is capable of mediating moderate ADCP via Fc&#x003b3;RI and Fc&#x003b3;RIIa. Therefore, a rise in spike-specific IgG4 can compete with other IgG subclasses to impede ADCP, especially when SARS-CoV-2 IgG titers are high. However, when SARS-CoV-2 IgG titers are low, IgG4 works in synergy with other subclasses to enhance ADCP, suggesting that elevated IgG4 titers can be beneficial for ADCP. Furthermore, both experimentally and using in silico models, we demonstrate that in scenarios where SARS-CoV-2 IgG titers are low, such as against emerging novel variants, the presence of elevated IgG4 titers may be beneficial for Fc&#x003b3;RI- and Fc&#x003b3;RIIa-driven Fc functions. Collectively, our work highlights the complex interplay of multiple features involved in Fc-mediated responses modulated by elevated SARS-CoV-2 IgG4.</p></sec><sec sec-type="results" disp-level="1"><title>RESULTS</title><sec disp-level="2"><title>Increased IgG4 following repeated SARS-CoV-2 mRNA vaccination is negatively correlated with Fc&#x003b3;R binding capacity</title><p>Plasma samples were collected from SARS-CoV-2 na&#x000ef;ve individuals 1 month post-second and post-third dose of mRNA vaccination (table S1). Plasma was assessed for SARS-CoV-2 antigen-specific IgG subclasses (<xref rid="F1" ref-type="fig">Fig. 1, A to D</xref>) using a SARS-CoV-2 multiplex bead assay. A small but significant increase in IgG1 (<italic toggle="yes">P</italic> &#x0003c; 0.01; <xref rid="F1" ref-type="fig">Fig. 1A</xref>) and a modest decrease in IgG3 (<italic toggle="yes">P</italic> &#x0003c; 0.0001; <xref rid="F1" ref-type="fig">Fig. 1C</xref>) were observed between the second and third mRNA doses. In contrast, a significant increase in spike-specific IgG4 (<italic toggle="yes">P</italic> &#x0003c; 0.0001; <xref rid="F1" ref-type="fig">Fig. 1D</xref>) was observed following the third dose.</p><fig position="float" id="F1" fig-type="image" specific-use="distribute"><label>Fig. 1.</label><caption><title>Increased IgG4 following repeated mRNA vaccination is negatively correlated with Fc&#x003b3;R immune complex formation.</title><p>Relative concentration of SARS-CoV-2 ancestral spike trimer-specific (<bold>A</bold>) IgG1, (<bold>B</bold>) IgG2, (<bold>C</bold>) IgG3, and (<bold>D</bold>) IgG4 in plasma collected 1 month (median = 28 days post-vaccination) post-dose two (<italic toggle="yes">n</italic> = 46) and three (<italic toggle="yes">n</italic> = 31) of BNT162b2 vaccine as measured by multiplex. Statistical significance was assessed using Mann-Whitney <italic toggle="yes">U</italic> test. (<bold>E</bold>) Two-tailed Spearman correlation between WT SARS-CoV-2 antigen-specific IgG1 to IgG4 and Fc&#x003b3;R (Fc&#x003b3;RIIa-H131, Fc&#x003b3;RIIa-R131, Fc&#x003b3;RIIIa-V158, and Fc&#x003b3;RIII-F158) binding. *<italic toggle="yes">P</italic> &#x0003c; &#x02212;0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001, and ****<italic toggle="yes">P</italic> &#x0003c; 0.0001. RBD, receptor binding domain.</p></caption><graphic xlink:href="sciadv.ads1482-f1" position="float"/></fig><p>IgG4 is often associated with reduced Fc functions due to its poor ability to engage with Fc&#x003b3;Rs (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>, <xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>). Previous studies have demonstrated that elevated IgG4 is accompanied by a reduction in spike-specific Fc-mediated responses (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>). To confirm this, we measured the ability of post-vaccination plasma to engage with soluble Fc&#x003b3;RIIa and Fc&#x003b3;RIIIa dimers as a surrogate measurement for ADCP and ADCC, respectively. We did not observe a decrease in Fc&#x003b3;R dimer binding following the third dose when testing with equivalent plasma dilutions (1:1600), although a significant decrease in Fc&#x003b3;RIIIaV binding was observed when responses were normalized to spike-specific total IgG, in accordance with previous published studies (<italic toggle="yes">P</italic> &#x0003c; 0.0001; fig. S1) (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>). We further interrogated the relationship between IgG subclasses and Fc&#x003b3;R engagement. IgG1 titers against all tested antigens displayed strong positive correlations with binding to all tested Fc&#x003b3;Rs (Fc&#x003b3;RIIa: Fc&#x003b3;RIIa-131R or Fc&#x003b3;RIIa-131H, Fc&#x003b3;RIIIa: Fc&#x003b3;RIIIa-158 V or Fc&#x003b3;RIIIa-158F), while weaker positive correlations between IgG3 titers and Fc&#x003b3;R binding were observed (<xref rid="F1" ref-type="fig">Fig. 1E</xref>). In contrast, IgG4 titers were negatively correlated with Fc&#x003b3;R engagement; thus, we next aimed to determine whether elevated IgG4 could potentially reduce Fc&#x003b3;R-mediated functions.</p></sec><sec disp-level="2"><title>IgG4 inhibits ADCC in a dose-dependent manner</title><p>To explore the potential inhibitory role of IgG4, we generated a cocktail of IgG4 monoclonal antibodies (mAbs) consisting of three previously characterized SARS-CoV-2 mAbs, all with high affinity for ancestral SARS-CoV-2 receptor binding domain (RBD) and are of different RBD classes (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>). We confirmed that subclass switching did not affect antigen binding (figs. S2 and S3 and tables S2 and S3) and that the IgG4 mAbs engaged different Fc&#x003b3;R classes and polymorphisms as expected, with overall high affinity to Fc&#x003b3;RI similar to IgG1, but weaker binding to Fc&#x003b3;RIIa-131H/R and very low or no binding to Fc&#x003b3;RIIIa-158 V/F (figs. S2 and S3 and tables S2 and S3).</p><p>IgG4 has been described to be a poor inducer of ADCC (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>, <xref rid="R22" ref-type="bibr"><italic toggle="yes">22</italic></xref>, <xref rid="R23" ref-type="bibr"><italic toggle="yes">23</italic></xref>). To confirm this, we added the IgG4 mAb cocktail into a subset of dose two mRNA vaccinated plasma samples (<italic toggle="yes">n</italic> = 24), mimicking elevated IgG4 observed following dose three mRNA vaccination, and assessed binding to soluble Fc&#x003b3;RIIIa dimers. When IgG4 was added to a concentration corresponding to the median concentration observed post-dose three (0.05 nM; 0.007 &#x003bc;g/ml) binding to either Fc&#x003b3;RIIIa polymorphism was not significantly different (<xref rid="F2" ref-type="fig">Fig. 2A</xref>) (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>). As we did not have matched post-dose four vaccination samples, we also performed IgG4 addition at a higher concentration (0.2 nM; 0.029 &#x003bc;g/ml), which corresponded to the median IgG4 concentration of a small subset of post dose four samples (fig. S4). The higher concentration of IgG4 addition significantly decreased Fc&#x003b3;RIIIa-158 V/F binding (<italic toggle="yes">P</italic> &#x0003c; 0.0001; <xref rid="F2" ref-type="fig">Fig. 2B</xref> and fig. S5).</p><fig position="float" id="F2" fig-type="image" specific-use="distribute"><label>Fig. 2.</label><caption><title>IgG4 reduces Fc&#x003b3;RIIIa binding and ADCC in dose-dependent manner.</title><p>(<bold>A</bold> and <bold>B</bold>) Change in binding of ancestral spike trimer-specific plasma antibodies to soluble Fc&#x003b3;RIIIa-V158 and Fc&#x003b3;RIIIa-F158 dimers following the addition of IgG4 mAb cocktails into post-dose two plasma. (<bold>C</bold>) Comparison of ancestral spike-specific IgG titers post-dose two BNT162b2 vaccination (<italic toggle="yes">n</italic> = 24) and following addition of 0.05 nM (0.007 &#x003bc;g/ml) or 0.2 nM (0.029 &#x003bc;g/ml) of IgG4 SARS-CoV-2 mAbs. (<bold>D</bold> to <bold>G</bold>) Change in IgG1-IgG4 titers following IgG4 addition into plasma. Significant differences were assessed using Friedman&#x02019;s test with Dunn&#x02019;s multiple comparison. Error bars indicate interquartile range. Binding of (<bold>H</bold>) IgG1 and (<bold>I</bold>) IgG4 mAb cocktails to IgG1 or IgG4 detection reagents, Fc&#x003b3;RIIIa-V158 and Fc&#x003b3;RIIIa-F158 dimers. The normalized median fluorescent intensity (MFI) of each detection reagent was plotted. (<bold>J</bold>) Comparison of the ability of IgG1 and IgG4 mAb cocktails to induce ADCC. (<bold>K</bold>) Fc&#x003b3;RIIIaV and Fc&#x003b3;RIIIaF binding of IgG4 mAb cocktail into IgG1 mAb cocktail (2.5 nM/0.365 &#x003bc;g/ml). (<bold>L</bold>) ADCC mediated by IgG4 mAb cocktails titrated into IgG1 mAb cocktail (10 nM; 1.46 &#x003bc;g/ml). Error bars indicate SEM. Curves were fitted using a four-parameter nonlinear regression model. ****<italic toggle="yes">P</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="sciadv.ads1482-f2" position="float"/></fig><p>To investigate the mechanism behind the differences in response between the two IgG4 concentrations, we assessed antigen-bound IgG1 to IgG4 titers before and after IgG4 addition (<xref rid="F2" ref-type="fig">Fig. 2, C to G</xref>). Spike-bound IgG1 and IgG3 titers were not significantly different following low-concentration IgG4 addition (0.05 nM) and collectively made up most of the antigen-bound IgG (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). In contrast, spike-bound IgG1 and IgG3 were significantly reduced following 0.2 nM addition of IgG4 (IgG1: <italic toggle="yes">P</italic> &#x0003c; 0.0001; IgG3: <italic toggle="yes">P</italic> &#x0003c; 0.05; <xref rid="F2" ref-type="fig">Fig. 2, D and F</xref>, and fig. S5), suggesting that high concentrations of IgG4 may be outcompeting other subclasses for antigen.</p><p>To confirm that elevated IgG4 reduces ADCC responses, we performed a previously described primary natural killer (NK) cell ADCC assay against spike-expressing target cells (<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>). The IgG1 mAbs induced potent ADCC and formed immune complexes with soluble Fc&#x003b3;RIIIa-158 V/F (<xref rid="F2" ref-type="fig">Fig. 2, H and J</xref>, and fig. S3), whereas the IgG4 mAbs was unable to induce ADCC above background levels and displayed poor and no measurable binding to Fc&#x003b3;RIIIa-158 V and Fc&#x003b3;RIIIa-158F, respectively (<xref rid="F2" ref-type="fig">Fig. 2, I and J</xref>, and fig. S3). Last, titrating the IgG4 mAb cocktail into the IgG1 mAb cocktail demonstrated that IgG4 reduced Fc&#x003b3;RIIIa binding and ADCC in a concentration-dependent manner (<xref rid="F2" ref-type="fig">Fig. 2, K and L</xref>). Collectively, these results demonstrate that excessive IgG4 can inhibit Fc&#x003b3;RIIIa binding and ADCC.</p></sec><sec disp-level="2"><title>Elevated IgG4 titers can enhance ADCP when total SARS-CoV-2 titers are low</title><p>We next investigated the influence of elevated levels of IgG4 upon ADCP by adding the IgG4 cocktail to dose two mRNA-vaccinated plasma samples using a previously described SARS-CoV-2 bead-based ADCP assay (<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>, <xref rid="R25" ref-type="bibr"><italic toggle="yes">25</italic></xref>). Unexpectedly, we observed that 67% of vaccinees displayed improved ADCP (&#x0003e;10% increase in phagocytic score; <xref rid="F3" ref-type="fig">Fig. 3A</xref>, blue lines) (<italic toggle="yes">P</italic> &#x0003c; 0.01). We confirmed this was mediated via a FcR-dependent manner by repeating the IgG4 spiking in the presence of an Fc block, which did not result in phagocytosis above background (fig. S6B). Given that these results contrasted with previous findings suggesting that IgG4 inhibits ADCP induction (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>), we examined the ability of the IgG4 mAb cocktails alone to induce ADCP. We found that the IgG4 mAbs were capable of mediating moderate ADCP, albeit reduced compared to IgG1 [IgG1 median effective concentration (EC<sub>50</sub>): 0.009 nM versus IgG4 EC50: 0.044 nM; <xref rid="F3" ref-type="fig">Fig. 3B</xref>]. Therefore, we hypothesized that IgG4 addition into plasma may enhance ADCP by working in synergy with other SARS-CoV-2 antibodies when total titers are low. Whereas when SARS-CoV-2 antibody titers are high, the addition of IgG4 may sterically hinder or outcompete IgG1 for antigen and/or Fc&#x003b3;R engagement, thus reducing ADCP.</p><fig position="float" id="F3" fig-type="image" specific-use="distribute"><label>Fig. 3.</label><caption><title>Change in ADCP and Fc&#x003b3;R engagement following IgG4 addition into post second dose BNT162b2 plasma.</title><p>(<bold>A</bold>) ADCP activity of plasma collected post-dose two of BNT162b2 vaccination (<italic toggle="yes">n</italic> = 24) before and after addition of IgG4 SARS-CoV-2 mAb cocktail. (<bold>B</bold>) ADCP activity induced by IgG1 (pink) and IgG4 (blue) mAb cocktails. (<bold>C</bold>) ADCP of ancestral spike-coated beads mediated by IgG4 mAb cocktail titrated into IgG1 mAb cocktail at 1 nM (0.146 &#x003bc;g/ml; red) or 0.1 nM (0.015 &#x003bc;g/ml; blue). Change in total IgG and IgG subclass distribution of spike-bound antibodies in individuals with (<bold>D</bold> to <bold>H</bold>) low total IgG (below median IgG titer) and (<bold>I</bold> to <bold>M</bold>) high total IgG (above median IgG titer) post-dose two and following addition IgG4. (<bold>N</bold> and <bold>O</bold>) Log change in Fc&#x003b3;RI, Fc&#x003b3;RIIa-H131, and Fc&#x003b3;RIIa-R131 binding following (N) 0.05 nM (0.007 &#x003bc;g/ml) and (O) 0.2 nM (0.029 &#x003bc;g/ml) IgG4 addition into post-dose two plasma. Significant differences were assessed using Friedman&#x02019;s test with Dunn&#x02019;s multiple comparison. Binding of (<bold>P</bold>) IgG1 and (<bold>Q</bold>) IgG4 mAb cocktails to IgG1 or IgG4 detection reagents and recombinant soluble Fc&#x003b3;RI, Fc&#x003b3;RIIa-H131, and Fc&#x003b3;RIIa-R131. The normalized MFI of each detection reagent was plotted. (<bold>R</bold> and <bold>S</bold>) Fc&#x003b3;RI and Fc&#x003b3;RIIa binding of IgG4 mAb cocktail titrated into IgG1 mAb cocktail at (R) saturating (2.5 nM/0.365 &#x003bc;g/ml) or (S) half-maximal binding (EC<sub>50</sub>; 0.3 nM/0.044 &#x003bc;g/ml) IgG1 concentration and binding to Fc&#x003b3;Rs were assessed. Curves were fitted using a four-parameter nonlinear regression model. (<bold>T</bold>) Model predictions for Fc&#x003b3;RIIa-H131 and Fc&#x003b3;RIIa-R131 immune complex formation were compared with multiplex experimental measurements. Landscape illustrating the relationship between IgG1 and IgG4 concentrations for predicting (<bold>U</bold>) Fc&#x003b3;RIIa-H131 and (<bold>V</bold>) and Fc&#x003b3;RIIa-R131 immune complex formation. Colour indicated the predicted change in complex formation from baseline (blue, decrease; red, increase). *<italic toggle="yes">P</italic> &#x0003c; 0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001, and ****<italic toggle="yes">P</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="sciadv.ads1482-f3" position="float"/></fig><p>To demonstrate this, we titrated the IgG4 mAbs into a fixed high concentration of IgG1 mAb cocktail (1 nM; 0.146 &#x003bc;g/ml) and assessed for ADCP. The addition of IgG4 reduced IgG1-mediated ADCP (29% reduction at 1:1 IgG1:IgG4 ratio; <xref rid="F3" ref-type="fig">Fig. 3C</xref>, red line), demonstrating that IgG4 can inhibit ADCP. In contrast, titrating IgG4 into a lower concentration of IgG1 (0.1 nM; 0.015 &#x003bc;g/ml) enhanced ADCP (80% enhancement at the highest concentration of IgG4 added; <xref rid="F3" ref-type="fig">Fig. 3C</xref>, blue line). Collectively, our results propose two different consequences of elevated IgG4 upon ADCP depending on total SARS-CoV-2 IgG titers. When IgG titers are high, IgG4 competes with other subclasses for antigen and/or Fc&#x003b3;R binding, leading to a reduction of ADCP. However, when titers are low, increased IgG4 results in more antigen-bound antibody, leading to an overall increase in ADCP.</p><p>To further investigate the role of total spike-specific IgG titers upon ADCP responses, we divided our cohort based on their SARS-CoV-2 spike-specific IgG concentrations post-second dose mRNA vaccination (low/high spike-specific total titers) and examined subclass composition of their spike-specific IgG before and after IgG4 addition (<xref rid="F3" ref-type="fig">Fig. 3, D to M</xref>, and fig. S5). In the low titer group, low concentration IgG4 addition did not significantly change antigen engagement by any subclass, except for IgG4 (<xref rid="F3" ref-type="fig">Fig. 3, D to H</xref>). In contrast, low concentration IgG4 addition caused a significant reduction in spike-bound IgG1 in the high titer group (<italic toggle="yes">P</italic> &#x0003c; 0.05; <xref rid="F3" ref-type="fig">Fig. 3J</xref>), and a trend toward reduced IgG3, albeit nonsignificant (<xref rid="F3" ref-type="fig">Fig. 3L</xref>). This suggests IgG4 competes with other subclasses for antigen binding when spike-specific titers are high, but this does not occur when titers are low.</p><p>As THP-1 monocytes express both Fc&#x003b3;RI and Fc&#x003b3;RII (fig. S6D), we assessed the impact of IgG4 addition on antigen-specific antibody engagement to soluble Fc&#x003b3;RI and Fc&#x003b3;RIIa. IgG4 spiking resulted in an overall increase in Fc&#x003b3;RI binding at both tested concentrations (0.05 nM IgG4, <italic toggle="yes">P</italic> &#x0003c; 0.05; 0.2 nM IgG4, <italic toggle="yes">P</italic> &#x0003c; 0.0001; <xref rid="F3" ref-type="fig">Fig. 3, N and O</xref>, and fig. S5). IgG4 addition resulted in heterogenous changes in Fc&#x003b3;RIIa engagement. In the low titer group, Fc&#x003b3;RIIaH and Fc&#x003b3;RIIaR binding improved following IgG4 addition at both concentrations (1.2-fold increase, <italic toggle="yes">P</italic> &#x0003c; 0.05; <xref rid="F3" ref-type="fig">Fig. 3, N and O</xref>, and fig. S5), suggesting that IgG4 is working in synergy with other subclasses to improve Fc&#x003b3;RIIa binding. Changes in Fc&#x003b3;RIIa binding varied in the high titer group depending on the polymorphism and concentration of IgG4 added. Binding to Fc&#x003b3;RIIaH did not change regardless of the concentration of IgG4 added. In contrast, the high titer group had improved Fc&#x003b3;RIIaR engagement following low concentration IgG4 addition (1.1-fold, <italic toggle="yes">P</italic> &#x0003c; 0.05; <xref rid="F3" ref-type="fig">Fig. 3N</xref>), but spiking of IgG4 at high concentrations did not result in any change in Fc&#x003b3;RIIaR binding (<xref rid="F3" ref-type="fig">Fig. 3, N and O</xref>). Collectively, these results suggests that presence of low IgG4 can enhance overall Fc&#x003b3;RI and Fc&#x003b3;RIIaR binding, especially when titers are low. Furthermore, our results highlight how IgG4 interacts differently with the two Fc&#x003b3;RIIa polymorphisms.</p><p>To gain a better understanding of the mechanism behind the induction and/or inhibition of Fc&#x003b3;RI and Fc&#x003b3;RIIa binding by IgG4, we used the mAb cocktails to mimic the different vaccine scenarios. We first confirmed the ability of the IgG1 and IgG4 mAb cocktails to form Fc&#x003b3;RI and Fc&#x003b3;RIIa immune complexes. As expected, IgG4 displayed lower binding to Fc&#x003b3;RIIaH and Fc&#x003b3;RIIaR compared to IgG1 (Fc&#x003b3;RIIaR EC<sub>50</sub> IgG1: 0.49 nM versus IgG4: 4.3 nM; Fc&#x003b3;RIIaH EC<sub>50</sub> IgG1: 0.49 nM versus IgG4: 19.3 nM; <xref rid="F3" ref-type="fig">Fig. 3, P and Q</xref>, and table S3), but both subclasses exhibited similar capacity to bind Fc&#x003b3;RI (IgG1 EC<sub>50</sub>: 0.39 nM; IgG4 EC<sub>50</sub>: 0.30 nM; <xref rid="F3" ref-type="fig">Fig. 3, P and Q</xref>). Similar to previous reports (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>), we observed higher binding of IgG4 to Fc&#x003b3;RIIaR than Fc&#x003b3;RIIaH (<xref rid="F3" ref-type="fig">Fig. 3Q</xref>), resulting in smaller differences in binding between IgG1 and IgG4 for Fc&#x003b3;RIIaR than for Fc&#x003b3;RIIaH (Fc&#x003b3;RIIaR EC<sub>50</sub> IgG1: 0.49 nM versus IgG4: 4.3 nM; Fc&#x003b3;RIIaH EC<sub>50</sub> IgG1: 0.49 nM versus IgG4: 19.3 nM), further supporting the differences that were observed between the two polymorphisms upon IgG4 addition to dose two plasma samples.</p><p>To further interrogate how the relationship between IgG4 and other subclasses influences Fc&#x003b3;RI and Fc&#x003b3;RIIa binding, we titrated IgG4 into a high fixed concentration of IgG1 (2.5 nM, 0.37 &#x003bc;g/ml). IgG4 addition had minimal impact on Fc&#x003b3;RI binding <xref rid="F3" ref-type="fig">Fig. 3R</xref>). In contrast, binding to both Fc&#x003b3;RIIa polymorphisms was reduced (<xref rid="F3" ref-type="fig">Fig. 3R</xref>); however, a greater reduction was seen for Fc&#x003b3;RIIaH compared to Fc&#x003b3;RIIaR (Fc&#x003b3;RIIaH: 24% reduction; Fc&#x003b3;RIIaR: 12% reduction at 1:1 IgG1:IgG4 ratio).</p><p>Last, we titrated the IgG4 cocktail into the IgG1 cocktail at approximately EC<sub>50</sub> concentration (0.3 nM, 0.04 &#x003bc;g/ml). At this concentration, IgG4 addition improved Fc&#x003b3;RI and Fc&#x003b3;RIIaR complex formation (Fc&#x003b3;RI: 60% increase, Fc&#x003b3;RIIaR: 35% increase; <xref rid="F3" ref-type="fig">Fig. 3S</xref>). However, Fc&#x003b3;RIIaH was reduced when excess IgG4 was added (19% reduction at 8:1 IgG4:IgG1 ratio) but had minimal effect (&#x0003c;10% difference in binding) when IgG4 was added at lower concentrations (<xref rid="F3" ref-type="fig">Fig. 3S</xref>), mirroring the changes in Fc&#x003b3;R binding observed following IgG4 addition into post-dose two plasma.</p></sec><sec disp-level="2"><title>In silico models confirm that IgG4 can enhance Fc&#x003b3;RIIa binding when IgG1 titers are low but inhibits Fc functions at high IgG1 titers</title><p>To gain a further mechanistic understanding of the importance of spike-specific IgG titers relative to IgG4 titers in influencing Fc&#x003b3;RIIa immune complex formation, we applied a qualitative computational framework that utilizes a previously developed ordinary differential equation (ODE) model that predicts Fc effector functions following different IgG subclass distributions upon HIV vaccination (<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>, <xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>). First, we validated that the computational model accurately predicted Fc&#x003b3;RIIaH (Pearson &#x003c1; = 0.99) and Fc&#x003b3;RIIaH (&#x003c1; = 0.96) relative to experimental Fc&#x003b3;RIIa multiplex measurements (<xref rid="F3" ref-type="fig">Fig. 3T</xref>). We then used the model to predict Fc&#x003b3;RIIa immune complex formation as spike-specific IgG1 (the most abundant subclass), and IgG4 concentrations were simultaneously altered to reflect increases that may result from boosting (<xref rid="F3" ref-type="fig">Fig. 3, U and V</xref>). The resulting landscape illustrates that at lower IgG1 concentrations, the addition of low to moderate levels of IgG4 induce an upward incline in Fc&#x003b3;RIIa (<xref rid="F3" ref-type="fig">Fig. 3, U and V</xref>, blue regions), whereas the high addition of IgG4 even to lower concentrations of IgG1 resulted in a decreased change in Fc&#x003b3;RIIa immune complex formation, with the greatest decrease occurring when simultaneous high levels of IgG1 and IgG4 concentrations are present (<xref rid="F3" ref-type="fig">Fig. 3, U and V</xref>, red regions). Model dissection also confirmed that this mechanism is driven by changing levels of competition between IgG1 and IgG4 depending on IgG1 levels. Overall, this simulation provides quantitative confirmation for a dual role of IgG4, whereby it can either enhance or reduce ADCP, depending on an individual&#x02019;s original spike-specific IgG1 titers.</p></sec><sec disp-level="2"><title>IgG4 depletion confirms IgG4 can outcompete IgG1 and IgG3 for antigen binding and reduce Fc&#x003b3;RIIIa binding</title><p>Although the above IgG4 spiking assays suggest that IgG4 is detrimental for Fc&#x003b3;RIIIa-mediated responses but may enhance Fc&#x003b3;RIIa-mediated responses, we sought to characterize a more definitive role of IgG4 by depleting IgG4 from a subset of post-dose three plasma (<italic toggle="yes">n</italic> = 16). We confirmed that IgG4 was depleted by &#x0003e;75% in all samples [median 96%, interquartile range (IQR) 89 to 98%]. We next compared antigen affinity of bulk and IgG4-depleted plasma by biolayer interferometry (BLI). Given that plasma consists of polyclonal pools of antibodies, which are present at various concentrations, a dissociation constant equilibrium (<italic toggle="yes">K</italic><sub>d</sub>) is difficult to accurately calculate. Therefore, only the dissociation rate constant (<italic toggle="yes">k</italic><sub>dis</sub>), which is a concentration-independent measurement, was measured (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>, <xref rid="R29" ref-type="bibr"><italic toggle="yes">29</italic></xref>). We observed similar binding disassociation for both IgG4 depleted and undepleted plasma (fig. S7), suggesting that IgG4 had similar affinity to spike as other subclasses. We next investigated the contribution of IgG4 to Fc effector functions. The depletion of IgG4 allowed for other IgG subclasses to bind antigen, resulting in significantly higher spike-bound IgG1 and IgG3 (IgG1: 1.9-fold increase, <italic toggle="yes">P</italic> &#x0003c; 0.01; IgG3: 1.4-fold increase, <italic toggle="yes">P</italic> &#x0003c; 0.001; <xref rid="F4" ref-type="fig">Fig. 4, A and C</xref>). This also confirms that polyclonal spike-specific IgG4 can compete with IgG1 and IgG3 for antigen binding.</p><fig position="float" id="F4" fig-type="image" specific-use="distribute"><label>Fig. 4.</label><caption><title>IgG4 depletion and (Fab&#x02032;)<sub>2</sub> spiking confirms dual role of IgG4.</title><p>Comparison of (<bold>A</bold> to <bold>D</bold>) spike-bound IgG1 to IgG4 titers and (<bold>E</bold>) ADCP responses of plasma collected post dose three mRNA vaccination (<italic toggle="yes">n</italic> = 13, median = 28 days post-vaccination) and IgG4 depleted plasma. (<bold>F</bold>) Log change in binding to soluble Fc&#x003b3;Rs of post-dose three plasma following IgG4 depletion. Statistical significance was assessed using Wilcoxon test. Log change in binding to Fc&#x003b3;RIIa and Fc&#x003b3;RIIIa of post-dose two mRNA vaccination plasma (<italic toggle="yes">n</italic> = 24, median = 28 days post-vaccination) following (<bold>G</bold>) 0.05 nM (0.006 &#x003bc;g/ml) and (<bold>H</bold>) 0.2 nM (0.022 &#x003bc;g/ml) addition of (Fab)<sub>2</sub> fragments of IgG4 mAbs into. Significant differences were assessed using Friedman&#x02019;s test with Dunn&#x02019;s multiple comparison. *<italic toggle="yes">P</italic> &#x0003c; 0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001, and ****<italic toggle="yes">P</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="sciadv.ads1482-f4" position="float"/></fig><p>We next investigated the contribution of IgG4 to Fc effector functions by assessing ADCP responses and Fc&#x003b3;R binding. As with the spiking assays, we divided our cohort based on their total IgG titers post-IgG4 depletions. ADCP responses between IgG4-depleted and -undepleted plasma was not significantly different, regardless of total IgG titers (<xref rid="F4" ref-type="fig">Fig. 4E</xref>). Likewise, no differences in Fc&#x003b3;RI binding were observed between IgG-depleted and -undepleted plasma (<xref rid="F4" ref-type="fig">Fig. 4F</xref>), likely due to the comparable affinity of IgG1 and IgG4 for Fc&#x003b3;RI. Similar to IgG4 spiking, IgG4 depletion resulted in heterogenous changes to Fc&#x003b3;RIIa binding (<xref rid="F4" ref-type="fig">Fig. 4E</xref>). We found that individuals with high total IgG titers following depletion displayed improved Fc&#x003b3;RIIa binding upon IgG4 depletion (<italic toggle="yes">P</italic> &#x0003c; 0.05). In contrast, individuals with low IgG titers showed a trend of reduced Fc&#x003b3;RIIa binding following depletion, supporting previous observations that IgG4 can work in synergy with other subclasses to improve Fc&#x003b3;RIIa binding. Last, we observed a significant increase in Fc&#x003b3;RIIIa binding post-IgG4 depletion in the high titer group (<italic toggle="yes">P</italic> &#x0003c; 0.05) and a trend toward increased Fc&#x003b3;RIIIa binding post-depletion in the low titer group, confirming that elevated IgG4 inhibits Fc&#x003b3;RIIIa binding.</p></sec><sec disp-level="2"><title>(Fab&#x02032;)<sub>2</sub> spiking confirms outcompetition of IgG1 and IgG3 reduces Fc&#x003b3;R-mediated responses</title><p>To confirm that competition for antigen binding was driving reduced Fc&#x003b3;R-mediated responses, we repeated the IgG4 mAb spiking assays using the (Fab&#x02032;)<sub>2</sub> fragments of the IgG4 mAbs. As with IgG4 spiking, (Fab&#x02032;)<sub>2</sub> spiking reduced spike binding of IgG1 and IgG3 (fig. S8B). Low-concentration (Fab&#x02032;)<sub>2</sub> spiking either resulted in a decreases or no change in Fc&#x003b3;R binding regardless of IgG titers binding in individuals with low IgG (<xref rid="F4" ref-type="fig">Fig. 4F</xref>). High-concentration (Fab&#x02032;)<sub>2</sub> spiking significantly decreased binding to Fc&#x003b3;RIIa and Fc&#x003b3;RIIIa (<italic toggle="yes">P</italic> &#x0003c; 0.0001; <xref rid="F4" ref-type="fig">Fig. 4G</xref>). Collectively, this confirms that outcompetition of IgG1 and IgG3 for antigen binding decreases Fc&#x003b3;R engagement and that the Fc region of IgG4 drives the observed increase in Fc&#x003b3;RIIa engagement.</p></sec><sec disp-level="2"><title>IgG4 addition improves formation of Fc&#x003b3;RIIa immune complexes against SARS-CoV-2 variants</title><p>As our previous results highlight the importance of total spike-specific antibody titers in determining the influence of increased IgG4 on Fc effector functions and the limited knowledge surrounding the consequence of IgG4 on Fc-mediated responses against SARS-CoV-2 variants, we next investigated the influence of IgG4 on variant-specific Fc-mediated responses As expected, variant-specific IgG1 to IgG4 titers were lower compared to those against ancestral strain. Moreover, we observed a delay in variant-specific subclass switching and weaker negative correlations between variant-specific IgG4 and Fc&#x003b3;R binding (fig. S9, A to E). As the plasma samples were collected from COVID-19 na&#x000ef;ve individuals who only received ancestral strain mRNA vaccination, we assessed Fc-mediated responses against the Delta and Omicron BA.2 variants as representative novel variants (<xref rid="F5" ref-type="fig">Fig. 5</xref>). We divided our cohort based on their variant spike-specific IgG titers (high/low) and examined spike-specific subclass composition and Fc&#x003b3;R binding before and after IgG4 addition. We used the same IgG4 mAbs cocktails, which displays similar binding capacity to Delta in comparsion to the ancestral strain, but reduced binding to BA.2 as one clone does not bind to BA.2, while the other two mAbs display reduced binding to BA.2 (fig. S2 and tables S2 and S3).</p><fig position="float" id="F5" fig-type="image" specific-use="distribute"><label>Fig. 5.</label><caption><title>Influence of IgG4 on Fc&#x003b3;R mediated responses against SARS-CoV-2 variants.</title><p>(<bold>A</bold> to <bold>D</bold>) Comparison of [(A) to (D)] Delta and (<bold>E</bold> to <bold>H</bold>) BA.2 spike-bound IgG1 to IgG4 titers post-dose two BNT162b2 vaccination and following IgG4 addition. (<bold>I</bold> to <bold>L</bold>) Change in binding to soluble Fc&#x003b3;Rs of post-dose two Delta-specific or BA.2-specific antibodies following IgG4 mAb cocktail addition. Significant differences were assessed using Friedman&#x02019;s test with Dunn&#x02019;s multiple comparison. Error bars indicate interquartile range. Binding of (<bold>M</bold>) IgG1 and (<bold>N</bold>) IgG4 mAb cocktails to IgG1 or IgG4 detection reagents or recombinant soluble Fc&#x003b3;Rs against BA.2 Spike trimer. The normalized MFI of each detection reagent was plotted. (<bold>O</bold> to <bold>P</bold>) Fc&#x003b3;R binding activity of IgG4 mAb cocktail was titrated into IgG1 mAb cocktail and binding to Fc&#x003b3;Rs against BA.2 Spike. Error bars indicate SEM. Curves were fitted using a four-parameter nonlinear regression. *<italic toggle="yes">P</italic> &#x0003c; 0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001, and ****<italic toggle="yes">P</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="sciadv.ads1482-f5" position="float"/></fig><p>Low-concentration IgG4 addition did not significantly change Delta or BA.2 spike binding by IgG1 and IgG3, regardless of spike-specific titers, while high-concentration IgG4 addition significantly reduced Delta and BA.2 spike-binding by IgG1 and IgG3 (<xref rid="F5" ref-type="fig">Fig. 5, A to H</xref>). Consequently at low concentrations, IgG4 addition either enhanced or did not change binding to all tested Fc&#x003b3;Rs against both variants (<xref rid="F5" ref-type="fig">Fig. 5, I and J</xref>). However, IgG4 addition improved Fc&#x003b3;RI binding but reduced Fc&#x003b3;RIIIa-158 V/F binding (<xref rid="F5" ref-type="fig">Fig. 5, K and L</xref>). Moreover, Delta-specific Fc&#x003b3;RIIa-131H (1.3-fold, <italic toggle="yes">P</italic> &#x0003c; 0.05) and Fc&#x003b3;RIIa-131R (2.0-fold, <italic toggle="yes">P</italic> &#x0003c; 0.0001) binding increased in individuals with low Delta spike-specific titers, while individuals with high titers displayed a decrease in Fc&#x003b3;RIIaH binding (1.1-fold decrease, <italic toggle="yes">P</italic> &#x0003c; 0.01) and an increase in Fc&#x003b3;RIIaR binding (1.1-fold increase, <italic toggle="yes">P</italic> &#x0003c; 0.05). This was further confirmed when replicating conditions with IgG4 mAbs with IgG1 mAb cocktails (fig. S9, H and I).</p><p>High-concentration IgG4 addition significantly increased Fc&#x003b3;RI binding and decreased Fc&#x003b3;RIIIa binding as expected (<italic toggle="yes">P</italic> &#x0003c; 0.001) as expected as well as reduced BA.2-specific Fc&#x003b3;RIIaH in individuals with higher BA.2-specific IgG (<xref rid="F5" ref-type="fig">Fig. 5L</xref>). This may be due to the reduced ability of the mAbs to bind BA.2 (ancestral EC<sub>50</sub>: IgG1 = 0.16 nM, IgG4 = 0.19 nM; BA.2 EC<sub>50</sub>: IgG1 = 1.55 nM, IgG4 = 1.14 nM); thus, mAb-mediated Fc&#x003b3;R complex formation against BA.2 was also reduced (<xref rid="F5" ref-type="fig">Fig. 5, M and N</xref>). Furthermore, saturation against BA.2 was not observed at the same concentration of IgG1 cocktail where saturation was achieved for ancestral spike (2.5 nM). Consequently, titrating IgG4 into this concentration of IgG1 mirrored results observed when assessing for ancestral responses to IgG4 titration into low levels of IgG1, where we observed improvements in Fc&#x003b3;RIIaR and Fc&#x003b3;RI binding (<xref rid="F5" ref-type="fig">Fig. 5O</xref>). Fc&#x003b3;RIIaH binding was also enhanced when we repeated this with even lower concentrations of IgG1 mAbs (<xref rid="F5" ref-type="fig">Fig. 5P</xref>), emphasizing the functional capacity of IgG4 when total IgG titers are low.</p></sec></sec><sec sec-type="discussion" disp-level="1"><title>DISCUSSION</title><p>While the rise in IgG4 titers following repeated SARS-CoV-2 mRNA vaccination is well described (<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>&#x02013;<xref rid="R19" ref-type="bibr"><italic toggle="yes">19</italic></xref>), the clinical and functional impact of this phenomenon is still to be fully elucidated. Here, we demonstrated that elevated spike-specific IgG4 compete with other antibodies for antigen and/or Fc&#x003b3;R binding, especially when spike-specific IgG titers are high, resulting in a decrease in Fc effector responses. However, at low spike-specific titers, IgG4 can work in synergy with other subclasses to enhance Fc&#x003b3;RI and Fc&#x003b3;RIIa-mediated effector functions (summarized in <xref rid="F6" ref-type="fig">Fig. 6</xref>). This suggests elevated spike-specific IgG4 may be advantageous in circumstances where antibody titers are low, such as within immunocompromised individuals (<xref rid="R30" ref-type="bibr"><italic toggle="yes">30</italic></xref>) or in other anatomical sites, such as the mucosa (<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>, <xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>). Furthermore, we demonstrate the potential benefit of elevated IgG4 titers for novel variants, where low cross-reactive antibody immunity may be induced by vaccination (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>, <xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>).</p><fig position="float" id="F6" fig-type="image" specific-use="distribute"><label>Fig. 6.</label><caption><title>Schematic of the role of anti-spike IgG4 in mediating Fc effector functions against SARS-CoV-2.</title><p>(<bold>A</bold>) Summary of binding affinity of IgG4 to different Fc&#x003b3;Rs. (<bold>B</bold>) At high spike-specific IgG titers, elevated IgG4 competes with IgG1 and IgG3 for antigen binding, resulting in reduced Fc&#x003b3;RIIa binding and ADCP. (<bold>C</bold>) At low anti-spike titers, increased IgG4 increases total antigen-bound IgG, leading to an overall increase in Fc&#x003b3;RI and Fc&#x003b3;RIIa binding and therefore ADCP. (<bold>D</bold>) Elevated IgG4 reduces Fc&#x003b3;RIIIa engagement and ADCC because of the poor ability of IgG4 to bind Fc&#x003b3;RIIIa.</p></caption><graphic xlink:href="sciadv.ads1482-f6" position="float"/></fig><p>Consequently, we demonstrate that elevated IgG4 can impede Fc&#x003b3;RIIIa binding and ADCC. In contrast, we show that IgG4 can trigger ADCP by THP-1 monocytes via both Fc&#x003b3;RI and Fc&#x003b3;RIIa, consistent with a previous study demonstrating this using IgG4 HIV mAbs (<xref rid="R23" ref-type="bibr"><italic toggle="yes">23</italic></xref>). Now, the relative importance of ADCC compared to ADCP in providing protection against COVID-19 in humans is unclear, although some studies have observed elevated ADCC and/or Fc&#x003b3;RIIIa binding may be elevated in those with severe disease (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>, <xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>). If excessive ADCC does contribute to severe disease, then elevated IgG4 may be beneficial as it can dampen Fc&#x003b3;RIIIa-mediated responses. However, studies in animal models suggest that polyfunctional antibody responses that includes both ADCC and ADCP are correlated with vaccine efficacy (<xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>); thus, elevated IgG4 may reduce polyfunctional responses and vaccine induced protection. Note that Fc&#x003b3;RIIIa may also be involved in mediating ADCP and conversely Fc&#x003b3;RIIa may mediate ADCC (<xref rid="R34" ref-type="bibr"><italic toggle="yes">34</italic></xref>, <xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). Moreover, different effector cells may coexpress different Fc&#x003b3;Rs at varying proportions (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>, <xref rid="R37" ref-type="bibr"><italic toggle="yes">37</italic></xref>). Thus, additional studies dissecting the relative contribution of ADCC and ADCP in the context of SARS-CoV-2, while taking account diverse effector cell and their Fc&#x003b3;R repertoires is necessary to better understand both functional and clinical consequence of increased IgG4.</p><p>Here, we demonstrate that IgG4 was capable of higher levels of binding to Fc&#x003b3;RIIaR compared to Fc&#x003b3;RIIaH, highlighting the importance of Fc&#x003b3;R polymorphisms in determining overall Fc&#x003b3;R activation. The distribution of Fc&#x003b3;RIIa polymorphisms varies between different ethnicities and geographical locations. Fc&#x003b3;RIIaH is more prevalent among East Asian populations than European and African Americans (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>, <xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>); thus, our data suggest that different ethnic populations may benefit more from a rise in IgG4. Now, studies examining the association between Fc&#x003b3;R polymorphisms and COVID-19 vaccine efficacy are limited. Nonetheless, Fc&#x003b3;RIIaR has been associated with increased disease severity and mortality in both SARS-CoV-2 and SARS-CoV (<xref rid="R40" ref-type="bibr"><italic toggle="yes">40</italic></xref>, <xref rid="R41" ref-type="bibr"><italic toggle="yes">41</italic></xref>), albeit both studies occurring in a small cohort of a single population. Therefore, large genetic studies together with large vaccine efficacy data could be informative.</p><p>IgG4 addition into both plasma and IgG1 mAbs demonstrate that IgG4 can compete with other subclasses for antigen binding, and this phenomenon is concentration based. However, multiple factors beyond antibody concentration modulate level of competition between subclasses, including antigen affinity and epitope. Our IgG4 mAb spiking assays likely overestimates the antigen affinity of polyclonal IgG4. It is possible that lower affinity IgG4 may not compete with other subclasses at the concentration used here. However, our IgG4 spiking assays against BA.2, which our mAbs have reduced affinity to antigen, demonstrate that lower affinity IgG4 can outcompete other subclasses at high concentrations. However, we acknowledge our vaccinees induced lower BA.2-specific titers, and future studies should explore whether low-affinity IgG4 outcompetes other subclasses when total titers are high.</p><p>Moreover, we do not take into account that different subclasses may have different antigen affinity. IgG4 has been speculated to have the highest antigen affinity among all subclasses as it acquires the most somatic hypermutations among all four subclasses (<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>), which may allow IgG4 to outcompete other subclasses at lower concentrations. Conversely, IgG4 can undergo F(ab) arm exchange in vivo, whereby IgG4 forms half-molecules, which then recombines with other half-molecules (<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>). Because of the random nature of the exchange, this typically results in a bispecific antibody, which may reduce the avidity of IgG4 (<xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>). We did not observe differences in binding kinetics of depleted and undepleted plasma. However, an increase in binding of IgG1 and IgG3 to spike following IgG4 depletion suggests that polyclonal IgG4 has sufficiently high antigen affinity to compete with IgG1 and IgG3 for antigen binding. However, measuring antigen affinity of purified polyclonal IgG4 would be a more accurate measurement and should be performed in the future to improve understanding on the competition between subclasses.</p><p>In addition, the mAbs used here target a limited number of epitopes on RBD, which is not a true reflection of polyclonal pool that targets multiple epitopes on spike, including those outside the RBD. Furthermore, our experiments demonstrating competition between IgG1 and IgG4 mAbs may not reflect what occurs in vivo where different subclasses may recognize distinct epitopes. Hence, future studies should aim to investigate IgG4 against epitopes beyond RBD, especially those that are highly conserved across variants and whether these overlap with epitopes recognized by other subclasses. These factors should also be taken into account along with the different subclass affinities to various Fc&#x003b3;Rs to better understand the importance of antigen binding compared to Fc receptor binding in the induction of Fc-mediated response.</p><p>As mentioned previously, the tendency of IgG4 to form bispecific antibodies that behaves as if functionally monovalent is thought to contribute to its reduced capacity to trigger Fc&#x003b3;R mediated responses, which often require cross-linking of multiple antigen-specific IgG (<xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>). While we did not assess if Fab arm exchange was occurring in our IgG4 mAb cocktail, it is unlikely that immune complex formation is substantially affected should it occur as the target epitopes are in proximity of each other. Future studies should investigate the role of Fab arm exchange on Fc&#x003b3;R-mediated responses and the overall consequence of Fc effector functions against SARS-CoV-2.</p><p>Overall, our study highlights the complex role of IgG4 in mediating Fc effector functions against SARS-CoV-2. While we have demonstrated that IgG4 exhibits reduced ability to trigger Fc effector functions such as ADCC and ADCP compared to IgG1, the relative contribution of IgG4 in the overall Fc&#x003b3;R-mediated response against SARS-CoV-2 was dependent on the titers of each IgG subclass, Fc&#x003b3;R class, and polymorphism as well as the target SARS-CoV-2 variant. Collectively, this study emphasizes the interconnected nature of the various factors modulating Fc effector functions. Our work highlights the need for future studies to examine the clinical impact of IgG4 against COVID-19 and to take into consideration the multiple factors that can potentially influence the functional consequences of IgG4.</p></sec><sec sec-type="materials|methods" disp-level="1"><title>MATERIALS AND METHODS</title><sec disp-level="2"><title>Human samples and ethics statement</title><p>SARS-CoV-2 vaccinee plasma was collected 13 to 42 days post-second (<italic toggle="yes">n</italic> = 46) and post-third (<italic toggle="yes">n</italic> = 31) dose of BNT162b2 (Pfizer-BioNTech) vaccination as previously described (<xref rid="R45" ref-type="bibr"><italic toggle="yes">45</italic></xref>). Participant characteristics are described in table S1. Informed consent was acquired from all participants. Study protocols were approved by the University of Melbourne Human Research Ethics Committee (#2056689, #21560, #21626, and #13344), Austin Health (#HREC/73256/Austin-2021), and Melbourne Health (HREC/68355/MH-2020).</p></sec><sec disp-level="2"><title>Expression of SARS-CoV-2-specific mAbs</title><p>Spike-specific IgG1 and IgG4 mAbs were expressed as previously described (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>). PDI 96, PDI 215, and PDI 222 were previously isolated from RBD-reactive B cells from patients with convalescent COVID-19 and cloned into human IgG1 expression vectors (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>). Class-switched PDI mAb constructs were obtained from GenScript. Expi293F suspension cells were transfected with heavy and light chain plasmids using the ExpiFectamine293 Kit (Life Technologies) according to the manufacturer&#x02019;s instructions. The cells were harvested after 4 to 5 days, and the antibodies purified by Protein A affinity chromatography.</p></sec><sec disp-level="2"><title>BLI of SARS-CoV-2 mAbs</title><p>Binding of the mAbs to SARS-CoV-2 RBD and human Fc&#x003b3;Rs was measured by BLI using an Octet-Red96 system (Fort&#x000e9;Bio) in black 96-well plates (Greiner Bio-One) at 30&#x000b0;C agitated at 1000 rpm. HBS-EP buffer [containing 0.01 M Hepes, 0.15 M NaCl, 3 mM EDTA, 0.005% (v/v) Surfactant P20, 0.005% Tween 20 (pH 7.4)] was used as the kinetic buffer for all assays.</p><p>BLI measuring affinity of the mAbs against human Fc&#x003b3;Rs were carried out using Streptavidin Biosensors (Fort&#x000e9;Bio). Biotinylated Fc&#x003b3;RIIa or Fc&#x003b3;RIIIa (5 &#x003bc;g/ml; ACROBiosystems) were loaded onto hydrated sensors until a threshold of 2 nm was reached, followed by equilibration in buffer only wells for 120 s. The sensors were loaded into a twofold dilution series of mAbs from 27.56 to 441 nM for 180 s to measure association. Dissociation was measured by submerging the sensors into buffer only wells for 300 s. Sensor tips were regenerated using a cycle of 5 s in 10 mM glycine (pH 3.0) and 5 s in kinetic buffer repeated three times. For measurement of affinity to Fc&#x003b3;RI, biotinylated mAbs (1.5 &#x003bc;g/ml) were loaded onto hydrated sensors until a threshold of 2 nm was reached, followed by equilibration in buffer only wells for 120 s. The sensors were loaded into a twofold dilution series of Fc&#x003b3;RI (R&#x00026;D Systems) from 2 to 30 nM for 150 s. Dissociation was measured by submerging the sensors into buffer only wells for 300 s. Affinity measurements against SARS-CoV-2 ancestral and variant RBD (SinoBiological) were performed using Protein G Biosensors (Fort&#x000e9;Bio) and carried out as previously described (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>).</p></sec><sec disp-level="2"><title>IgG4 spiking assays</title><p>PDI 96, PDI 215, and PDI 222 were pooled to form an IgG4 mAb cocktail. PDI 222 is part of cluster 1 and is of the VH1&#x02013;58 class that binds the RBD at an epitope centered around N487. PDI 215 is part of cluster 4 and binds the distal part of the RBD outside the angiotensin-converting enzyme 2 (ACE2) receptor binding site. PDI 96 is part of cluster 6 and binds to the ACE2 binding site at G446 and T500 (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>). IgG4 mAb cocktail was added into plasma collected post-dose two mRNA vaccination at 0.05 nM (0.007 &#x003bc;g/ml) to represent the median IgG4 concentration measured in our cohort post-third dose mRNA vaccination. Spiking at 0.2 nM (0.029 &#x003bc;g/ml) corresponded to the median IgG4 concentration of a subset of post-dose four mRNA samples (<italic toggle="yes">n</italic> = 6).</p></sec><sec disp-level="2"><title>(Fab&#x02032;)<sub>2</sub> spiking</title><p>Digestion of IgG4 (Fab&#x02032;)<sub>2</sub> fragments was performed by incubation of 100 &#x003bc;l of IgG4 mAb cocktail (0.5 mg/ml) with 80 &#x003bc;l of FabRICATOR MagIC resin (Genovis) at 37&#x000b0;C for 20 min with continuous mixing, followed by the removal of the resin by magnetic separation. IgG4 (Fab)<sub>2</sub> ftragments were added to post-dose two plasma at a concentration of 0.05 nM (0.006 &#x003bc;g/ml) or 0.2 nM (0.022 &#x003bc;g/msl).</p></sec><sec disp-level="2"><title>IgG4 depletion</title><p>Plasma was diluted 1:5 in phosphate-buffered saline (PBS) before addition of 5 &#x003bc;l of resuspended CaptureSelect IgG4 (Hu) Affinity Matrix (Invitrogen) and incubated on a vortex at room temperature (RT) for 1 hour. Following incubation, the samples were centrifuge for 1 min, and the supernatant was collected. A Luminex multiplex assay was performed to assess efficient IgG4 depletion. Sufficient depletion was defined as &#x0003e;75% reduction in IgG4 relative to the undepleted sample. Depleted samples with IgG4 levels greater than the 25th percentile IgG4 level measured at dose two were excluded from subsequent analysis.</p></sec><sec disp-level="2"><title>SARS-CoV-2 multiplex bead assay</title><p>A customized Luminex multiplex assay was used to assess mAb and plasma SARS-CoV-2 antibody responses as previously described (<xref rid="R46" ref-type="bibr"><italic toggle="yes">46</italic></xref>). Briefly, mAbs or plasma (1:1600) was incubated with antigen-coupled beads (750 beads/bead region; table S4) on a shaker overnight at 4&#x000b0;C before being washed with PBS 0.05% Tween 20 (PBST). Following washing, the beads were incubated with biotinylated or phycoerythrin (PE)&#x02013;conjugated detection antibodies or soluble Fc receptors (table S5) on a shaker for 2 hours at RT. For biotinylated detectors, plates were followed with an additional PBST wash and incubated with streptavidin-R&#x02013;PE (Invitrogen) for 2 hours at RT. The plates were washed, and each well was resuspended sheath fluid before reading on the xMAP INTELLIFLEX (Luminex). The level of PE signal associated with each bead region in each well was reported as median fluorescence intensity (MFI). The MFI of buffer only wells were background subtracted for each sample. Standard curves were generated using IgG1 to IgG4 anti&#x02013;SARS-CoV-2 RBD broadly neutralizing mAbs (AM395b, Acro Biosystems). A four-parameter logistic regression was used to convert the MFI of plasma samples to antigen-specific IgG1 to IgG4 concentrations, relative to the standard curve. Individuals with total relative antigen-specific IgG titers below the median were classified as low titer, and individuals with total titers above the median were classified as high titer. Each sample was run in duplicate.</p></sec><sec disp-level="2"><title>Bead-based THP-1 ADCP assay</title><p>ADCP was measured using a previously described bead-based ADCP assay (<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>, <xref rid="R25" ref-type="bibr"><italic toggle="yes">25</italic></xref>). Briefly, SARS-CoV-2 ancestral spike trimer and RBD (SinoBiological) were biotinylated and coupled to 1 &#x003bc;M fluorescent NeutrAvidin Fluospheres (beads; Invitrogen) overnight at 4&#x000b0;C. Washed antigen-coated beads were incubated with plasma (1:3200) or mAbs for 2 hours at 37&#x000b0;C in a 96-well U-bottom plate before addition of THP-1 monocytes (100,000 per well) followed by a 16-hour incubation under cell culture conditions. For Fc block experiments, THP-1 monocytes were incubated BD Pharmingen Human BD Fc Block at RT for 20 min (2.5 &#x003bc;g/1 million cells) before addition to opsonized beads. Cells were fixed and acquired by flow cytometry on a BD LSR Fortessa with a high-throughput sampler attachment (HTS) (see fig. S3A for gating). The data were analyzed using FlowJo 10.9.0, and a phagocytic score was calculated as previously described using the formula: (% bead-positive cells &#x000d7; mean fluorescent intensity). Flow cytometry was used to confirm stable expression of Fc&#x003b3;RI (CD64), Fc&#x003b3;RII (CD32), and Fc&#x003b1;R (CD89) (table S4) on THP-1 monocytes before use.</p></sec><sec disp-level="2"><title>Luciferase-based ADCC assay</title><p>ADCC was examined using a previously described luciferase-based ADCC assay (<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>). NK cells from healthy donors were enriched and purified using the EasySep Human NK Cell Enrichment Kit (STEMCELL Technologies Inc.) NK cells (20,000 per well) and Ramos S-Luc cells (5000 per well) were added to 96-well V-bottom cell culture plates and incubated with threefold dilutions of mAb cocktail for 4 hours at 37&#x000b0;C. Each condition was tested in duplicate, and &#x0201c;no antibody&#x0201d; and &#x0201c;target cell only&#x0201d; controls were included. Following incubation, cells were washed and developed with britelite plus luciferase reagent (Revvity). Luminescence was read using a FLUOstar Omega microplate reader (BMG Labtech). The relative light units measured was used to calculate % ADCC with the formula: (&#x0201c;no antibody&#x0201d; &#x02212; &#x0201c;antibody sample&#x0201d;)/(&#x0201c;target cell only&#x0201d;) &#x000d7; 100.</p></sec><sec disp-level="2"><title>BLI measurements of IgG4-depleted and undepleted plasma</title><p>To measure binding kinetics of IgG4-depleted plasma and undepleted plasma to spike, hydrated streptavidin sensors were loaded with biotinylated ancestral SARS-CoV-2 spike trimer (5 &#x003bc;g/ml) until a threshold of 1.6 nm was reached, followed by equilibration in buffer only wells for 60 s. The sensors were submerged in a twofold dilution series of plasma or IgG4-depleted plasma, starting from a 1 in 400 dilution, for 180 s to allow for association. Dissociation was measured by submerging sensors into buffer only wells for 300 s. Only the dissociation rate constant (kdis), which is a concentration-independent measurement was measured, given that plasma consists of polyclonal antibodies (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>, <xref rid="R29" ref-type="bibr"><italic toggle="yes">29</italic></xref>). Curve fitting was performed using a local fit 1:1 Langmuir binding model for plasma. Baseline drift was corrected by reference subtracting the shift of a loaded sensor immersed in kinetic buffer only. Mean kinetic constant and SEM were determined from two independent experiments.</p></sec><sec disp-level="2"><title>Data normalization</title><p>The antibody MFI and phagocytic score of each mAb cocktail was normalized to the maximum antibody binding or phagocytic score (100%). The normalized antibody binding or phagocytic score was used to calculate the half maximal effective concentration (EC<sub>50</sub>). For IgG4 mAb cocktail titration into IgG1 mAb cocktail experiments, the antibody MFI, phagocytic score, or % ADCC of IgG1 + IgG4 mAb cocktails were normalized to the antibody binding, phagocytic score, or % ADCC of the IgG1 mAb cocktail alone.</p></sec><sec disp-level="2"><title>In silico Fc&#x003b3;R ODE model generation and validation</title><p>Fc&#x003b3;RIIa binding simulations were carried out using a previously published ODE model (<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>) implemented in MATLAB (R2023b, MathWorks) that predicts Fc&#x003b3;R complex formation as a function of IgG subclass concentrations. Model parameters are outlined in table S6. The model was used to predict Fc&#x003b3;RIIa-131H and Fc&#x003b3;RIIa-131R complex formation as a function of measured IgG subclass concentrations for each dose 2 mRNA-vaccinated plasma samples. To fit the model to the data, measured IgG concentrations were proportionally adjusted by a constant factor (&#x003bb; = 25) to maximize the fit with the corresponding predictions from the corresponding multiplex assay measurements. Code and data used for these models are available at <ext-link xlink:href="https://doi.org/10.5281/zenodo.14231188" ext-link-type="uri">https://doi.org/10.5281/zenodo.14231188</ext-link>.</p></sec><sec disp-level="2"><title>Surface plots to evaluate the combined effects of IgG1 and IgG4</title><p>Fc&#x003b3;R complex formation surfaces were generated by simulating the model across 50 IgG1 concentrations and 100 IgG4 concentrations logarithmically spaced from 0.10 to 10 nM and 0.045 to 7.5 nM respectively to cover the plasma concentration range observed before and after the addition of IgG4 mAb. IgG2 and IgG3 levels were set to the median values in the dose two mRNA-vaccinated samples. Surface color was determined by numerical approximation of the partial derivative of Fc&#x003b3;R complex formation with respect to IgG4 concentration at each IgG1 and IgG4 combination (gradient function).</p></sec><sec disp-level="2"><title>Statistical analysis</title><p>Prism GraphPad version 10.1.0 (GraphPad Software) was used to develop graphs and perform the statistical analyses described in the figure legends. The EC<sub>50</sub> of each mAb or mAb cocktail was determined using a four-parameter nonlinear regression model describing the relationship between the agonist concentration and the normalized response.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We thank the vaccine participants for their generous time and gracious provision of samples. We thank T. Amarasena, K. Wragg, P. Konstandopoulus, G. Gare, K. Field, H. Kelly (University of Melbourne), G. Gibney, and F. James (Austin Health) for the outstanding technical assistance. We acknowledge the Melbourne Cytometry Platform for provision of flow cytometry services. We thank W-H. Tham, L. Tan, and P. Pymm (WEHI) for providing SARS-CoV-2 RBD.</p><sec><p><bold>Funding:</bold> This study is supported by the Medical Research Future Fund (MRFF) GNT #2016062 to J.A.J., J.A.T., T.H.N., K.K., A.K.W., S.J.K., and A.W.C. and an NHMRC Investigator grant #2008093 to A.W.C. J.A.J. is supported by a Sylvia and Chatles Viertel Senior Medical Research Fellowships. W.S.L., J.A.J., T.H.N., K.K., A.K.W., and S.J.K. are also supported by NHMRC Investigator grants.</p></sec><sec><p><bold>Author contributions:</bold> Conceptualization: L.C.A., R.A.P., R.M.T., A.K., K.K., S.J.K., K.B.A., and A.W.C. Data curation: L.C.A., R.A.P., J.A.J., K.A.B., D.A.W., J.A.T., K.K., A.W.C. Formal analysis: L.C.A., R.A.P., R.M.T., P.R., J.A.T., K.K., K.B.A., and A.W.C. Funding acquisition: J.A.J., J.A.T., T.H.N., K.K., A.K.W., S.J.K., and A.W.C. Investigation: L.C.A., R.A.P., A.K., R.E., D.A.W., J.M.T., J.A.T., K.K., S.J.K., and A.W.C. Methodology: L.C.A., R.A.P., R.M.T., W.S.L., P.M.H., D.A.W., J.M.T., K.K., K.B.A., K.J.S., and A.W.C. Project administration: D.A.W., J.A.J., S.J.K., and A.W.C. Resources: A.K., R.E., W.S.L., B.D.W., P.M.H., J.A.J., L.F.A., K.A.B., D.A.W., J.M.T., T.H.N., K.K., A.K.W., S.J.K., K.B.A., and A.W.C. Software: R.M.T. Supervision: K.K., A.K.W., K.B.A., K.J.S., and A.W.C. Validation: L.C.A., D.A.W., and A.W.C. Visualization: L.C.A., R.M.T., K.B.A., K.J.S., and A.W.C. Writing&#x02014;original draft: L.C.A. and A.W.C. Writing&#x02014;reviewing and editing: All authors.</p></sec><sec><p><bold>Competing interests:</bold> The authors declare that they have no competing interests.</p></sec><sec><p><bold>Data and materials availability:</bold> Data included in this study is available via the following repository: https://doi.org/10.5281/zenodo.14695518. All other data needed to evaluate the conclusions are present in the paper and/or the supplementary materials.</p></sec></ack><sec sec-type="supplementary-material"><title>Supplementary Materials</title><sec><title>This PDF file includes:</title><supplementary-material position="float" content-type="local-data"><caption><p>Figs. S1 to S9</p><p>Tables S1 to S6</p></caption><media xlink:href="sciadv.ads1482_sm.pdf"/></supplementary-material></sec></sec><ref-list><title>REFERENCES AND NOTES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. S.</given-names>
<surname>Khoury</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Cromer</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Reynaldi</surname></string-name>, <string-name><given-names>T. E.</given-names>
<surname>Schlub</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Subbarao</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Triccas</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Davenport</surname></string-name></person-group>, 
<article-title>Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection</article-title>. <source>Nat. Med.</source>
<volume>27</volume>, 
<fpage>1205</fpage>&#x02013;<lpage>1211</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34002089</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Zohar</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Loos</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fischinger</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Atyeo</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>M. D.</given-names>
<surname>Slein</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Burke</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Feldman</surname></string-name>, <string-name><given-names>B. M.</given-names>
<surname>Hauser</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Caradonna</surname></string-name>, <string-name><given-names>A. G.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Cai</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Streeck</surname></string-name>, <string-name><given-names>E. T.</given-names>
<surname>Ryan</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Barouch</surname></string-name>, <string-name><given-names>R. C.</given-names>
<surname>Charles</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Lauffenburger</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Alter</surname></string-name></person-group>, 
<article-title>Compromised humoral functional evolution tracks with SARS-CoV-2 mortality</article-title>. <source>Cell</source>
<volume>183</volume>, 
<fpage>1508</fpage>&#x02013;<lpage>1519.e12</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33207184</pub-id>
</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Atyeo</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fischinger</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Zohar</surname></string-name>, <string-name><given-names>M. D.</given-names>
<surname>Slein</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Burke</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Loos</surname></string-name>, <string-name><given-names>D. J.</given-names>
<surname>McCulloch</surname></string-name>, <string-name><given-names>K. L.</given-names>
<surname>Newman</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Wolf</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Shuey</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Feldman</surname></string-name>, <string-name><given-names>B. M.</given-names>
<surname>Hauser</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Caradonna</surname></string-name>, <string-name><given-names>A. G.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>T. J.</given-names>
<surname>Suscovich</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Linde</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Cai</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Barouch</surname></string-name>, <string-name><given-names>E. T.</given-names>
<surname>Ryan</surname></string-name>, <string-name><given-names>R. C.</given-names>
<surname>Charles</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Lauffenburger</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Chu</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Alter</surname></string-name></person-group>, 
<article-title>Distinct early serological signatures track with SARS-CoV-2 survival</article-title>. <source>Immunity</source>
<volume>53</volume>, 
<fpage>524</fpage>&#x02013;<lpage>532.e4</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32783920</pub-id>
</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Sch&#x000e4;fer</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Muecksch</surname></string-name>, <string-name><given-names>J. C. C.</given-names>
<surname>Lorenzi</surname></string-name>, <string-name><given-names>S. R.</given-names>
<surname>Leist</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Cipolla</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bournazos</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Maison</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Gazumyan</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Martinez</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Baric</surname></string-name>, <string-name><given-names>D. F.</given-names>
<surname>Robbiani</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Hatziioannou</surname></string-name>, <string-name><given-names>J. V.</given-names>
<surname>Ravetch</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Bieniasz</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Nussenzweig</surname></string-name>, <string-name><given-names>T. P.</given-names>
<surname>Sheahan</surname></string-name></person-group>, 
<article-title>Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo</article-title>. <source>J. Exp. Med.</source>
<volume>218</volume>, 
<fpage>e20201993</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33211088</pub-id>
</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. B.</given-names>
<surname>Arnold</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name></person-group>, 
<article-title>Prospects from systems serology research</article-title>. <source>Immunology</source>
<volume>153</volume>, 
<fpage>279</fpage>&#x02013;<lpage>289</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29139548</pub-id>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. R.</given-names>
<surname>Mackin</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Desai</surname></string-name>, <string-name><given-names>B. M.</given-names>
<surname>Whitener</surname></string-name>, <string-name><given-names>C. E.</given-names>
<surname>Karl</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Baric</surname></string-name>, <string-name><given-names>D. K.</given-names>
<surname>Edwards</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Chicz</surname></string-name>, <string-name><given-names>R. P.</given-names>
<surname>McNamara</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Alter</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Diamond</surname></string-name></person-group>, 
<article-title>Fc-&#x003b3;R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2</article-title>. <source>Nat. Microbiol.</source>
<volume>8</volume>, 
<fpage>569</fpage>&#x02013;<lpage>580</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37012355</pub-id>
</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. R.</given-names>
<surname>Haycroft</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Ramanathan</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Lopez</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Purcell</surname></string-name>, <string-name><given-names>L. L.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Pymm</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Wines</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Hogarth</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Redmond</surname></string-name>, <string-name><given-names>N. A.</given-names>
<surname>Gherardin</surname></string-name>, <string-name><given-names>D. I.</given-names>
<surname>Godfrey</surname></string-name>, <string-name><given-names>W. H.</given-names>
<surname>Tham</surname></string-name>, <string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name></person-group>, 
<article-title>Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants</article-title>. <source>Med. Microbiol. Immunol.</source>
<volume>212</volume>, 
<fpage>291</fpage>&#x02013;<lpage>305</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37477828</pub-id>
</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Kaplonek</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fischinger</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Cizmeci</surname></string-name>, <string-name><given-names>Y. C.</given-names>
<surname>Bartsch</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Kang</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Burke</surname></string-name>, <string-name><given-names>S. A.</given-names>
<surname>Shin</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Dayal</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Martin</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Mann</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Amanat</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Julg</surname></string-name>, <string-name><given-names>E. J.</given-names>
<surname>Nilles</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Musk</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Menon</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Krammer</surname></string-name>, <string-name><given-names>E. O.</given-names>
<surname>Saphire</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Andrea</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Alter</surname></string-name></person-group>, 
<article-title>mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern</article-title>. <source>Immunity</source>
<volume>55</volume>, 
<fpage>355</fpage>&#x02013;<lpage>365.e4</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35090580</pub-id>
</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. I.</given-names>
<surname>Richardson</surname></string-name>, <string-name><given-names>N. P.</given-names>
<surname>Manamela</surname></string-name>, <string-name><given-names>B. M.</given-names>
<surname>Motsoeneng</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kaldine</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Ayres</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Makhado</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Mennen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Skelem</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Williams</surname></string-name>, <string-name><given-names>N. J.</given-names>
<surname>Sullivan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Misasi</surname></string-name>, <string-name><given-names>G. G.</given-names>
<surname>Gray</surname></string-name>, <string-name><given-names>L.-G.</given-names>
<surname>Bekker</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Ueckermann</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Rossouw</surname></string-name>, <string-name><given-names>M. T.</given-names>
<surname>Boswell</surname></string-name>, <string-name><given-names>N. A. B.</given-names>
<surname>Ntusi</surname></string-name>, <string-name><given-names>W. A.</given-names>
<surname>Burgers</surname></string-name>, <string-name><given-names>P. L.</given-names>
<surname>Moore</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity</article-title>. <source>Cell Rep. Med.</source>
<volume>3</volume>, 
<fpage>100510</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35233544</pub-id>
</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Vidarsson</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Dekkers</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Rispens</surname></string-name></person-group>, 
<article-title>IgG Subclasses and allotypes: From structure to effector functions</article-title>. <source>Front. Immunol.</source>
<volume>5</volume>, 
<fpage>520</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25368619</pub-id>
</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Bruhns</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Iannascoli</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>England</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Mancardi</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Fernandez</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jorieux</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Da&#x000eb;ron</surname></string-name></person-group>, 
<article-title>Specificity and affinity of human Fc&#x003b3; receptors and their polymorphic variants for human IgG subclasses</article-title>. <source>Blood</source>
<volume>113</volume>, 
<fpage>3716</fpage>&#x02013;<lpage>3725</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19018092</pub-id>
</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ghebremichael</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Robinson</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Brown</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Choi</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Lane</surname></string-name>, <string-name><given-names>A.-S.</given-names>
<surname>Dugast</surname></string-name>, <string-name><given-names>M. K.</given-names>
<surname>Schoen</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rolland</surname></string-name>, <string-name><given-names>T. J.</given-names>
<surname>Suscovich</surname></string-name>, <string-name><given-names>A. E.</given-names>
<surname>Mahan</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Liao</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Streeck</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Andrews</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rerks-Ngarm</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Nitayaphan</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>de Souza</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Kaewkungwal</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Pitisuttithum</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Francis</surname></string-name>, <string-name><given-names>N. L.</given-names>
<surname>Michael</surname></string-name>, <string-name><given-names>J. H.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Bailey-Kellogg</surname></string-name>, <string-name><given-names>M. E.</given-names>
<surname>Ackerman</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Alter</surname></string-name></person-group>, 
<article-title>Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines</article-title>. <source>Sci. Transl. Med.</source>
<volume>6</volume>, 
<fpage>228ra38</fpage> (<year>2014</year>).</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Damelang</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Rogerson</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name></person-group>, 
<article-title>Role of IgG3 in infectious diseases</article-title>. <source>Trends Immunol.</source>
<volume>40</volume>, 
<fpage>197</fpage>&#x02013;<lpage>211</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30745265</pub-id>
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. N.</given-names>
<surname>Forthal</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Landucci</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Ding</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Kappes</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Thung</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Phan</surname></string-name></person-group>, 
<article-title>IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation</article-title>. <source>AIDS</source>
<volume>25</volume>, 
<fpage>2099</fpage>&#x02013;<lpage>2104</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21832933</pub-id>
</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Karagiannis</surname></string-name>, <string-name><given-names>A. E.</given-names>
<surname>Gilbert</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Josephs</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Ali</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Dodev</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Saul</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Correa</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Roberts</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Beddowes</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Koers</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hobbs</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ferreira</surname></string-name>, <string-name><given-names>J. L. C.</given-names>
<surname>Geh</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Healy</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Harries</surname></string-name>, <string-name><given-names>K. M.</given-names>
<surname>Acland</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Blower</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Mitchell</surname></string-name>, <string-name><given-names>D. J.</given-names>
<surname>Fear</surname></string-name>, <string-name><given-names>J. F.</given-names>
<surname>Spicer</surname></string-name>, <string-name><given-names>K. E.</given-names>
<surname>Lacy</surname></string-name>, <string-name><given-names>F. O.</given-names>
<surname>Nestle</surname></string-name>, <string-name><given-names>S. N.</given-names>
<surname>Karagiannis</surname></string-name></person-group>, 
<article-title>IgG4 subclass antibodies impair antitumor immunity in melanoma</article-title>. <source>J. Clin. Invest.</source>
<volume>123</volume>, 
<fpage>1457</fpage>&#x02013;<lpage>1474</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23454746</pub-id>
</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Ramanathan</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Haycroft</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Reynaldi</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Cromer</surname></string-name>, <string-name><given-names>C. W.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>L. F.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Wines</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Hogarth</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Downie</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Purcell</surname></string-name>, <string-name><given-names>H. E.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Davenport</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name></person-group>, 
<article-title>Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections</article-title>. <source>JCI Insight</source>
<volume>8</volume>, <fpage>e172470</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37737263</pub-id>
</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Irrgang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Gerling</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Kocher</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Lapuente</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Steininger</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Habenicht</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Wytopil</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Beileke</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Sch&#x000e4;fer</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhong</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ssebyatika</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Krey</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Falcone</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Sch&#x000fc;lein</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Peter</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Nganou-Makamdop</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Hengel</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Held</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Bogdan</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>&#x000dc;berla</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Schober</surname></string-name>, <string-name><given-names>T. H.</given-names>
<surname>Winkler</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Tenbusch</surname></string-name></person-group>, 
<article-title>Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination</article-title>. <source>Sci. Immunol.</source>
<volume>8</volume>, (<year>2023</year>).</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N.</given-names>
<surname>Lasrado</surname></string-name>, <string-name><given-names>A.-R. Y.</given-names>
<surname>Collier</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Miller</surname></string-name>, <string-name><given-names>N. P.</given-names>
<surname>Hachmann</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Anand</surname></string-name>, <string-name><given-names>E. A.</given-names>
<surname>Bondzie</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Fisher</surname></string-name>, <string-name><given-names>C. R.</given-names>
<surname>Mazurek</surname></string-name>, <string-name><given-names>R. C.</given-names>
<surname>Patio</surname></string-name>, <string-name><given-names>S. L.</given-names>
<surname>Rodrigues</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rowe</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Surve</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Ty</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Chicz</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Tong</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Korber</surname></string-name>, <string-name><given-names>R. P.</given-names>
<surname>Mcnamara</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Barouch</surname></string-name></person-group>, 
<article-title>Waning immunity and IgG4 responses following bivalent mRNA boosting</article-title>. <source>Sci. Adv.</source>
<volume>8</volume>, 
<fpage>eadj9945</fpage> (<year>2024</year>).</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Kalkeri</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Zhu</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cloney-Clark</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Plested</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Parekh</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Gorinson</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Cai</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Mahato</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Ramanathan</surname></string-name>, <string-name><given-names>L. C.</given-names>
<surname>Aurelia</surname></string-name>, <string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Marchese</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Fries</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>L. M.</given-names>
<surname>Dunkle</surname></string-name></person-group>, 
<article-title>Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines</article-title>. <source>J. Infect.</source>
<volume>88</volume>, 
<fpage>106119</fpage> (<year>2024</year>).<pub-id pub-id-type="pmid">38360356</pub-id>
</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Rispens</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Huijbers</surname></string-name></person-group>, 
<article-title>The unique properties of IgG4 and its roles in health and disease</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>23</volume>, 
<fpage>763</fpage>&#x02013;<lpage>778</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37095254</pub-id>
</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Pymm</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Esterbauer</surname></string-name>, <string-name><given-names>M. H.</given-names>
<surname>Dietrich</surname></string-name>, <string-name><given-names>W. S.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Drew</surname></string-name>, <string-name><given-names>H. G.</given-names>
<surname>Kelly</surname></string-name>, <string-name><given-names>L.-J.</given-names>
<surname>Chan</surname></string-name>, <string-name><given-names>F. L.</given-names>
<surname>Mordant</surname></string-name>, <string-name><given-names>K. A.</given-names>
<surname>Black</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Adair</surname></string-name>, <string-name><given-names>H.-X.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>K. M.</given-names>
<surname>Wragg</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Amarasena</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Lopez</surname></string-name>, <string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Haycroft</surname></string-name>, <string-name><given-names>J. P.</given-names>
<surname>Cooney</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Venugopal</surname></string-name>, <string-name><given-names>L. L.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>M. T. O.</given-names>
<surname>Neill</surname></string-name>, <string-name><given-names>C. C.</given-names>
<surname>Allison</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Cromer</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Davenport</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Pellegrini</surname></string-name>, <string-name><given-names>M. T.</given-names>
<surname>Liddament</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Glukhova</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Subbarao</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>W.-H.</given-names>
<surname>Tham</surname></string-name></person-group>, 
<article-title>Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain</article-title>. <source>Cell Rep.</source>
<volume>37</volume>, 
<fpage>109822</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34610292</pub-id>
</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Br&#x000fc;ggemann</surname></string-name>, <string-name><given-names>G. T.</given-names>
<surname>Williams</surname></string-name>, <string-name><given-names>C. I.</given-names>
<surname>Bindon</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Clark</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Walker</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Jefferis</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Waldmann</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Neuberger</surname></string-name></person-group>, 
<article-title>Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies</article-title>. <source>J. Exp. Med.</source>
<volume>166</volume>, 
<fpage>1351</fpage>&#x02013;<lpage>1361</lpage> (<year>1987</year>).<pub-id pub-id-type="pmid">3500259</pub-id>
</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. M.</given-names>
<surname>Brady</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Phelps</surname></string-name>, <string-name><given-names>S. W.</given-names>
<surname>MacDonald</surname></string-name>, <string-name><given-names>E. C.</given-names>
<surname>Lam</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Nitido</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Parsons</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Boutros</surname></string-name>, <string-name><given-names>C. E.</given-names>
<surname>Deal</surname></string-name>, <string-name><given-names>W. F.</given-names>
<surname>Garcia-Beltran</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Tanno</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Natarajan</surname></string-name>, <string-name><given-names>M. E.</given-names>
<surname>Ackerman</surname></string-name>, <string-name><given-names>V. D.</given-names>
<surname>Vrbanac</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>Balazs</surname></string-name></person-group>, 
<article-title>Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice</article-title>. <source>Sci. Transl. Med.</source>
<volume>14</volume>, 
<fpage>eabn9662</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35895834</pub-id>
</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W. S.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Wines</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Reynaldi</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Esterbauer</surname></string-name>, <string-name><given-names>H. G.</given-names>
<surname>Kelly</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Haycroft</surname></string-name>, <string-name><given-names>H. X.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Hogarth</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Cromer</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Davenport</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name></person-group>, 
<article-title>Decay of Fc-dependent antibody functions after mild to moderate COVID-19</article-title>. <source>Cell Rep. Med.</source>
<volume>2</volume>, 
<fpage>100296</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33997824</pub-id>
</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. K.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Lopez</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Haycroft</surname></string-name>, <string-name><given-names>W. S.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Adair</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Pymm</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Redmond</surname></string-name>, <string-name><given-names>N. A.</given-names>
<surname>Gherardin</surname></string-name>, <string-name><given-names>D. I.</given-names>
<surname>Godfrey</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Tham</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name></person-group>, 
<article-title>Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma</article-title>. <source>Clin. Transl. Immunology</source>
<volume>11</volume>, 
<fpage>e1424</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36299410</pub-id>
</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. M.</given-names>
<surname>Lemke</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>McLean</surname></string-name>, <string-name><given-names>C. Y.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Lopez</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Bozich</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rerks-Ngarm</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Pitisuttithum</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Nitayaphan</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kratochvil</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Wines</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Hogarth</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>K. B.</given-names>
<surname>Arnold</surname></string-name></person-group>, 
<article-title>A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination</article-title>. <source>Cell Rep. Med.</source>
<volume>2</volume>, 
<fpage>100386</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34622227</pub-id>
</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. M.</given-names>
<surname>Lemke</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Theisen</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Bozich</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>McLean</surname></string-name>, <string-name><given-names>C. Y.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Lopez</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rerks-Ngarm</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Pitisuttithum</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Nitayaphan</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kratochvil</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Wines</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Hogarth</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>K. B.</given-names>
<surname>Arnold</surname></string-name></person-group>, 
<article-title>A Quantitative approach to unravel the role of host genetics in IgG-Fc&#x003b3;R complex formation after vaccination</article-title>. <source>Front. Immunol.</source>
<volume>13</volume>, 
<fpage>820148</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35273603</pub-id>
</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P. J.</given-names>
<surname>Klasse</surname></string-name></person-group>, 
<article-title>How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses</article-title>. <source>Expert Rev. Vaccines</source>
<volume>15</volume>, 
<fpage>295</fpage>&#x02013;<lpage>311</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26641943</pub-id>
</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V.</given-names>
<surname>Madhavi</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Wines</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Amin</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Emery</surname></string-name>, <collab>ENCORE Study Group</collab>, <string-name><given-names>E.</given-names>
<surname>Lopez</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Kelleher</surname></string-name>, <collab>Sydney LTNP Study Group</collab>, <string-name><given-names>R. J.</given-names>
<surname>Center</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Hogarth</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Stratov</surname></string-name></person-group>, 
<article-title>HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV</article-title>. <source>J. Virol.</source>
<volume>91</volume>, 
<fpage>e00700-17</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28701393</pub-id>
</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. A.</given-names>
<surname>Purcell</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Theisen</surname></string-name>, <string-name><given-names>K. B.</given-names>
<surname>Arnold</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name></person-group>, 
<article-title>Polyfunctional antibodies: A path towards precision vaccines for vulnerable populations</article-title>. <source>Front. Immunol.</source>
<volume>14</volume>, <fpage>1183727</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37600816</pub-id>
</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Haycroft</surname></string-name>, <string-name><given-names>W. S.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Lopez</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Reynaldi</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Davenport</surname></string-name>, <string-name><given-names>H. E.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name></person-group>, 
<article-title>Tear antibodies to SARS-CoV-2: Implications for transmission</article-title>. <source>Clin. Transl. Immunology</source>
<volume>10</volume>, 
<fpage>e1354</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34754451</pub-id>
</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. E.</given-names>
<surname>Butler</surname></string-name>, <string-name><given-names>A. R.</given-names>
<surname>Crowley</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Natarajan</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Weiner</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Bobak</surname></string-name>, <string-name><given-names>D. E.</given-names>
<surname>Mattox</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Wieland-Alter</surname></string-name>, <string-name><given-names>R. I.</given-names>
<surname>Connor</surname></string-name>, <string-name><given-names>P. F.</given-names>
<surname>Wright</surname></string-name>, <string-name><given-names>M. E.</given-names>
<surname>Ackerman</surname></string-name></person-group>, 
<article-title>Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals</article-title>. <source>Front. Immunol.</source>
<volume>11</volume>, 
<fpage>618685</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33584712</pub-id>
</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names>
<surname>McMahan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>N. B.</given-names>
<surname>Mercado</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Loos</surname></string-name>, <string-name><given-names>L. H.</given-names>
<surname>Tostanoski</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Chandrashekar</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Peter</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Atyeo</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Zhu</surname></string-name>, <string-name><given-names>E. A.</given-names>
<surname>Bondzie</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Dagotto</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Gebre</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Jacob-Dolan</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Nampanya</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Patel</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Pessaint</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Van Ry</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Blade</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yalley-Ogunro</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Cabus</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Brown</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Cook</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Teow</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Andersen</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Lewis</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Lauffenburger</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Alter</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Barouch</surname></string-name></person-group>, 
<article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title>. <source>Nature</source>
<volume>590</volume>, 
<fpage>630</fpage>&#x02013;<lpage>634</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33276369</pub-id>
</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. F.</given-names>
<surname>Graziano</surname></string-name></person-group>, 
<article-title>Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells</article-title>. <source>J. Immunol.</source>
<volume>139</volume>, 
<fpage>3536</fpage>&#x02013;<lpage>3541</lpage> (<year>1987</year>).<pub-id pub-id-type="pmid">2960735</pub-id>
</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. L.</given-names>
<surname>Anderson</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Eicher</surname></string-name>, <string-name><given-names>M. D.</given-names>
<surname>Wewers</surname></string-name>, <string-name><given-names>J. K.</given-names>
<surname>Gill</surname></string-name></person-group>, 
<article-title>Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes</article-title>. <source>J. Exp. Med.</source>
<volume>171</volume>, 
<fpage>1333</fpage>&#x02013;<lpage>1345</lpage> (<year>1990</year>).<pub-id pub-id-type="pmid">2139103</pub-id>
</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. L.</given-names>
<surname>Anderson</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Loone</surname></string-name></person-group>, 
<article-title>Human leukocyte IgG Fc receptors</article-title>. <source>Immunol. Today</source>
<volume>7</volume>, 
<fpage>264</fpage>&#x02013;<lpage>266</lpage> (<year>1986</year>).<pub-id pub-id-type="pmid">25290629</pub-id>
</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. C.</given-names>
<surname>Unkeless</surname></string-name></person-group>, 
<article-title>Human Fc receptors for IgG</article-title>. <source>Int. Rev. Immunol.</source>
<volume>5</volume>, 
<fpage>165</fpage>&#x02013;<lpage>171</lpage> (<year>1989</year>).<pub-id pub-id-type="pmid">8691049</pub-id>
</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Lehrnbecher</surname></string-name>, <string-name><given-names>C. B.</given-names>
<surname>Foster</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Zhu</surname></string-name>, <string-name><given-names>S. F.</given-names>
<surname>Leitman</surname></string-name>, <string-name><given-names>L. R.</given-names>
<surname>Goldin</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Huppi</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Chanock</surname></string-name></person-group>, 
<article-title>Variant genotypes of the low-affinity Fc receptors in two control populations and a review of low-affinity Fc receptor polymorphisms in control and disease populations</article-title>. <source>Blood</source>
<volume>94</volume>, 
<fpage>4220</fpage>&#x02013;<lpage>4232</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10590067</pub-id>
</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. M.</given-names>
<surname>Osborne</surname></string-name>, <string-name><given-names>G. W.</given-names>
<surname>Chacko</surname></string-name>, <string-name><given-names>J. T.</given-names>
<surname>Brandt</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Anderson</surname></string-name></person-group>, 
<article-title>Ethnic variation in frequency of an allelic polymorphism of human FcyRIIA determined with allele specific oligonucleotide probes</article-title>. <source>J. Immunol. Methods</source>
<volume>173</volume>, 
<fpage>207</fpage>&#x02013;<lpage>217</lpage> (<year>1994</year>).<pub-id pub-id-type="pmid">8046255</pub-id>
</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>L&#x000f3;pez-Mart&#x000ed;nez</surname></string-name>, <string-name><given-names>G. M.</given-names>
<surname>Albaiceta</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Amado-Rodr&#x000ed;guez</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cuesta-Llavona</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>G&#x000f3;mez</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Garc&#x000ed;a-Clemente</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>V&#x000e1;zquez-Coto</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Alvarez</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Coto</surname></string-name></person-group>, 
<article-title>The FCGR2A rs1801274 polymorphism was associated with the risk of death among COVID-19 patients</article-title>. <source>Clin. Immunol.</source>
<volume>236</volume>, 
<fpage>108954</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35149195</pub-id>
</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>F. F.</given-names>
<surname>Yuan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Tanner</surname></string-name>, <string-name><given-names>P. K. S.</given-names>
<surname>Chan</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Biffin</surname></string-name>, <string-name><given-names>W. B.</given-names>
<surname>Dyer</surname></string-name>, <string-name><given-names>A. F.</given-names>
<surname>Geczy</surname></string-name>, <string-name><given-names>J. W.</given-names>
<surname>Tang</surname></string-name>, <string-name><given-names>D. S. C.</given-names>
<surname>Hui</surname></string-name>, <string-name><given-names>J. J. Y.</given-names>
<surname>Sung</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Sullivan</surname></string-name></person-group>, 
<article-title>Influence of <italic toggle="yes">Fc&#x003b3;RIIA</italic> and <italic toggle="yes">MBL</italic> polymorphisms on severe acute respiratory syndrome</article-title>. <source>Tissue Antigens</source>
<volume>66</volume>, 
<fpage>291</fpage>&#x02013;<lpage>296</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16185324</pub-id>
</mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names>
<surname>Kitaura</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Yamashita</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Ayabe</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Shini</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Matsutani</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Suzuki</surname></string-name></person-group>, 
<article-title>Different somatic hypermutation levels among antibody subclasses disclosed by a new next-generation sequencing-based antibody repertoire analysis</article-title>. <source>Front. Immunol.</source>
<volume>8</volume>, 
<fpage>389</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28515723</pub-id>
</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. J. L.</given-names>
<surname>Jackson</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Collins</surname></string-name></person-group>, 
<article-title>Human immunoglobulin classes and subclasses show variability in VDJ gene mutation levels</article-title>. <source>Immunol. Cell Biol.</source>
<volume>92</volume>, 
<fpage>729</fpage>&#x02013;<lpage>733</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24913324</pub-id>
</mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>van der Neut Kolfschoten</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Schuurman</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Losen</surname></string-name>, <string-name><given-names>W. K.</given-names>
<surname>Bleeker</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Vermeulen</surname></string-name>, <string-name><given-names>T. H.</given-names>
<surname>den Bleker</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wiegman</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Vink</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Aarden</surname></string-name>, <string-name><given-names>M. H.</given-names>
<surname>De Baets</surname></string-name>, <string-name><given-names>J. G. J.</given-names>
<surname>van de Winkel</surname></string-name>, <string-name><given-names>R. C.</given-names>
<surname>Aalberse</surname></string-name>, <string-name><given-names>P. W. H. I.</given-names>
<surname>Parren</surname></string-name></person-group>, 
<article-title>Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange</article-title>. <source>Science</source>
<volume>317</volume>, 
<fpage>1554</fpage>&#x02013;<lpage>1557</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17872445</pub-id>
</mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. A.</given-names>
<surname>Purcell</surname></string-name>, <string-name><given-names>L. C.</given-names>
<surname>Aurelia</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Esterbauer</surname></string-name>, <string-name><given-names>L. F.</given-names>
<surname>Allen</surname></string-name>, <string-name><given-names>K. A.</given-names>
<surname>Bond</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Williamson</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Trevillyan</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Trubiano</surname></string-name>, <string-name><given-names>J. J.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Davenport</surname></string-name>, <string-name><given-names>T. H. O.</given-names>
<surname>Nguyen</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Kedzierska</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name></person-group>, 
<article-title>Immunoglobulin G genetic variation can confound assessment of antibody levels via altered binding to detection reagents</article-title>. <source>Clin. Transl. Immunology</source>
<volume>13</volume>, 
<fpage>e1494</fpage> (<year>2024</year>).<pub-id pub-id-type="pmid">38433763</pub-id>
</mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. J.</given-names>
<surname>Selva</surname></string-name>, <string-name><given-names>C. E.</given-names>
<surname>van de Sandt</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>Lemke</surname></string-name>, <string-name><given-names>C. Y.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Shoffner</surname></string-name>, <string-name><given-names>B. Y.</given-names>
<surname>Chua</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>T. H. O.</given-names>
<surname>Nguyen</surname></string-name>, <string-name><given-names>L. C.</given-names>
<surname>Rowntree</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Hensen</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Koutsakos</surname></string-name>, <string-name><given-names>C. Y.</given-names>
<surname>Wong</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Mordant</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Jackson</surname></string-name>, <string-name><given-names>K. L.</given-names>
<surname>Flanagan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Crowe</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Tosif</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Neeland</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Sutton</surname></string-name>, <string-name><given-names>P. V.</given-names>
<surname>Licciardi</surname></string-name>, <string-name><given-names>N. W.</given-names>
<surname>Crawford</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Cheng</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Doolan</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Amanat</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Krammer</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Chappell</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Modhiran</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Watterson</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Young</surname></string-name>, <string-name><given-names>W. S.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Wines</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Hogarth</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Esterbauer</surname></string-name>, <string-name><given-names>H. G.</given-names>
<surname>Kelly</surname></string-name>, <string-name><given-names>H.-X.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Juno</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Kent</surname></string-name>, <string-name><given-names>K. B.</given-names>
<surname>Arnold</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Kedzierska</surname></string-name>, <string-name><given-names>A. W.</given-names>
<surname>Chung</surname></string-name></person-group>, 
<article-title>Systems serology detects functionally distinct coronavirus antibody features in children and elderly</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>, 
<fpage>2037</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33795692</pub-id>
</mixed-citation></ref></ref-list></back></article>